

Oligomeric amyloid \hat{I}^2 associates with postsynaptic density synapse loss near senile plaques

Proceedings of the National Academy of Sciences of the United States of America
106, 4012-4017

DOI: [10.1073/pnas.0811698106](https://doi.org/10.1073/pnas.0811698106)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Reporter of Local Dendritic Translocation Shows Plaque- Related Loss of Neural System Function in APP-Transgenic Mice. <i>Journal of Neuroscience</i> , 2009, 29, 12636-12640.	1.7	54
2	A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. <i>Brain Research</i> , 2009, 1280, 178-185.	1.1	20
3	Disruption of glutamate receptors at Shank-postsynaptic platform in Alzheimer's disease. <i>Brain Research</i> , 2009, 1292, 191-198.	1.1	87
4	Synaptic degeneration in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2009, 118, 167-179.	3.9	446
5	Membrane permeabilization by Islet Amyloid Polypeptide. <i>Chemistry and Physics of Lipids</i> , 2009, 160, 1-10.	1.5	116
6	β -Secretase elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. <i>European Journal of Neuroscience</i> , 2009, 30, 2271-2283.	1.2	105
7	Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. <i>Journal of Neurochemistry</i> , 2009, 111, 1409-1424.	2.1	99
8	The binding of pullulan modified cholesteryl nanogels to $A\beta$ oligomers and their suppression of cytotoxicity. <i>Biomaterials</i> , 2009, 30, 5583-5591.	5.7	88
9	Novel Pentameric Thiophene Derivatives for <i>in Vitro</i> and <i>in Vivo</i> Optical Imaging of a Plethora of Protein Aggregates in Cerebral Amyloidoses. <i>ACS Chemical Biology</i> , 2009, 4, 673-684.	1.6	290
10	Oligomeric aggregates of amyloid β peptide 1-42 activate ERK/MAPK in SH-SY5Y cells via the $\alpha 7$ nicotinic receptor. <i>Neurochemistry International</i> , 2009, 55, 796-801.	1.9	47
11	Amyloid- β (1-42) Fibrillar Precursors Are Optimal for Inducing Tumor Necrosis Factor- α Production in the THP-1 Human Monocytic Cell Line. <i>Biochemistry</i> , 2009, 48, 9011-9021.	1.2	19
12	Amyloid Goes Global. <i>Science Signaling</i> , 2009, 2, pe16.	1.6	18
13	Structural Polymorphism of Amyloid Oligomers and Fibrils Underlies Different Fibrillization Pathways: Immunogenicity and Cytotoxicity. <i>Current Protein and Peptide Science</i> , 2010, 11, 343-354.	0.7	33
14	Amyloid- β Peptide and Oligomers in the Brain and Cerebrospinal Fluid of Aged Canines. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 637-646.	1.2	69
15	Focal demyelination in Alzheimer's disease and transgenic mouse models. <i>Acta Neuropathologica</i> , 2010, 119, 567-577.	3.9	155
16	Amyloid β and APP as biomarkers for Alzheimer's disease. <i>Experimental Gerontology</i> , 2010, 45, 23-29.	1.2	104
17	Intracellular calcium signalling in Alzheimer's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 30-41.	1.6	58
18	Basic mechanisms of neurodegeneration: a critical update. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 457-487.	1.6	330

#	ARTICLE	IF	CITATIONS
19	Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid β oligomers. <i>Annals of Neurology</i> , 2010, 68, 220-230.	2.8	123
20	Amyloid β oligomers impair fear conditioned memory in a calcineurin ϵ -dependent fashion in mice. <i>Journal of Neuroscience Research</i> , 2010, 88, 2923-2932.	1.3	93
21	Despite its role in assembly, methionine 35 is not necessary for amyloid β -protein toxicity. <i>Journal of Neurochemistry</i> , 2010, 113, 1252-1262.	2.1	39
22	Progressive accumulation of amyloid β oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. <i>FEBS Journal</i> , 2010, 277, 3051-3067.	2.2	188
23	Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. <i>FEBS Journal</i> , 2010, 277, 4602-4613.	2.2	164
24	How hardwired is the brain? Technological advances provide new insight into brain malleability and neurotransmission. <i>Nutrition Reviews</i> , 2010, 68, S60-S64.	2.6	2
25	Oligomeric A β in Alzheimer's Disease: Relationship to Plaque and Tangle Pathology, <i>APOE</i> Genotype and Cerebral Amyloid Angiopathy. <i>Brain Pathology</i> , 2010, 20, 468-480.	2.1	57
26	In Vivo Imaging Biomarkers in Mouse Models of Alzheimer's Disease: Are We Lost in Translation or Breaking Through?. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-11.	1.1	11
27	Multiple Events Lead to Dendritic Spine Loss in Triple Transgenic Alzheimer's Disease Mice. <i>PLoS ONE</i> , 2010, 5, e15477.	1.1	145
28	Array Tomography: High-Resolution Three-Dimensional Immunofluorescence. <i>Cold Spring Harbor Protocols</i> , 2010, 2010, pdb.top89.	0.2	37
29	Alzheimer's Disease: A General Introduction and Pathomechanism. <i>Journal of Alzheimer's Disease</i> , 2010, 22, S5-S19.	1.2	143
30	Calpain Activation Promotes BACE1 Expression, Amyloid Precursor Protein Processing, and Amyloid Plaque Formation in a Transgenic Mouse Model of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2010, 285, 27737-27744.	1.6	96
31	Selective Vulnerability of Neurons in Layer II of the Entorhinal Cortex during Aging and Alzheimer's Disease. <i>Neural Plasticity</i> , 2010, 2010, 1-8.	1.0	143
32	Generation and Therapeutic Efficacy of Highly Oligomer-Specific β -Amyloid Antibodies. <i>Journal of Neuroscience</i> , 2010, 30, 10369-10379.	1.7	97
33	Alzheimer's Disease and the Amyloid- β Peptide. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 311-323.	1.2	1,270
34	Embryonic stem and haematopoietic progenitor cells resist to A β oligomer toxicity and maintain the differentiation potency in culture. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2010, 17, 137-145.	1.4	3
35	Molecular mechanisms of neurodegeneration in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2010, 19, R12-R20.	1.4	561
36	Astrocytes in Alzheimer's Disease: Emerging Roles in Calcium Dysregulation and Synaptic Plasticity. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 699-714.	1.2	78

#	ARTICLE	IF	CITATIONS
37	Amyloid- β as a Modulator of Synaptic Plasticity. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 741-763.	1.2	225
39	The Role of Microglia in Synaptic Stripping and Synaptic Degeneration: A Revised Perspective. <i>ASN Neuro</i> , 2010, 2, AN20100024.	1.5	117
40	A NH2 Tau Fragment Targets Neuronal Mitochondria at AD Synapses: Possible Implications for Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 445-470.	1.2	92
41	Back to the Plaque. <i>Annual Reports in Medicinal Chemistry</i> , 2010, 45, 314-328.	0.5	0
42	Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5. <i>Neuron</i> , 2010, 66, 739-754.	3.8	413
43	Probing the Biology of Alzheimer's Disease in Mice. <i>Neuron</i> , 2010, 66, 631-645.	3.8	382
44	Multiphoton in vivo imaging of amyloid in animal models of Alzheimer's disease. <i>Neuropharmacology</i> , 2010, 59, 268-275.	2.0	43
45	Review: Disruption of the Postsynaptic Density in Alzheimer's Disease and Other Neurodegenerative Dementias. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 547-555.	0.9	63
46	NOX Activity Is Increased in Mild Cognitive Impairment. <i>Antioxidants and Redox Signaling</i> , 2010, 12, 1371-1382.	2.5	89
47	Structure and Intermolecular Dynamics of Aggregates Populated during Amyloid Fibril Formation Studied by Hydrogen/Deuterium Exchange. <i>Accounts of Chemical Research</i> , 2010, 43, 1072-1079.	7.6	66
48	Amyloid β Induces the Morphological Neurodegenerative Triad of Spine Loss, Dendritic Simplification, and Neuritic Dystrophies through Calcineurin Activation. <i>Journal of Neuroscience</i> , 2010, 30, 2636-2649.	1.7	328
49	Monoclonal antibodies against β -amyloid ($A\beta$) for the treatment of Alzheimer's disease: the $A\beta$ target at a crossroads. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 679-686.	1.4	40
50	Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18837-18842.	3.3	228
51	Soluble amyloid β -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 5819-5824.	3.3	770
52	Sensing Amyloid- β Aggregation Using Luminescent Dipyridophenazine Ruthenium(II) Complexes. <i>Journal of the American Chemical Society</i> , 2011, 133, 11121-11123.	6.6	113
53	Regulation of Caspases in the Nervous System. <i>Progress in Molecular Biology and Translational Science</i> , 2011, 99, 265-305.	0.9	50
54	Neuropathological Alterations in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a006189-a006189.	2.9	2,365
55	$A\beta^{240}$ and $A\beta^{242}$ Amyloid Fibrils Exhibit Distinct Molecular Recycling Properties. <i>Journal of the American Chemical Society</i> , 2011, 133, 6505-6508.	6.6	93

#	ARTICLE	IF	CITATIONS
56	Conformer-Specific Hydrogen Exchange Analysis of A β (1-42) Oligomers by Top-Down Electron Capture Dissociation Mass Spectrometry. <i>Analytical Chemistry</i> , 2011, 83, 5386-5393.	3.2	62
57	Neuronal Differentiation of Human Mesenchymal Stromal Cells Increases their Resistance to A β ²⁴² Aggregate Toxicity. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 651-664.	1.2	9
58	Resolving controversies on the path to Alzheimer's therapeutics. <i>Nature Medicine</i> , 2011, 17, 1060-1065.	15.2	434
59	Tau Accumulation Causes Mitochondrial Distribution Deficits in Neurons in a Mouse Model of Tauopathy and in Human Alzheimer's Disease Brain. <i>American Journal of Pathology</i> , 2011, 179, 2071-2082.	1.9	224
60	Nanomechanics of functional and pathological amyloid materials. <i>Nature Nanotechnology</i> , 2011, 6, 469-479.	15.6	703
61	Passive (Amyloid- β) Immunotherapy Attenuates Monoaminergic Axonal Degeneration in the A β PPswE/PS1dE9 Mice. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 271-279.	1.2	16
64	CDK5 Is Essential for Soluble Amyloid β -Induced Degradation of GKAP and Remodeling of the Synaptic Actin Cytoskeleton. <i>PLoS ONE</i> , 2011, 6, e23097.	1.1	35
65	Grape Seed Polyphenolic Extract Specifically Decreases A β *56 in the Brains of Tg2576 Mice. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 657-666.	1.2	49
66	Brain Oligomeric β -Amyloid but Not Total Amyloid Plaque Burden Correlates With Neuronal Loss and Astrocyte Inflammatory Response in Amyloid Precursor Protein/Tau Transgenic Mice. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2011, 70, 360-376.	0.9	111
67	Aggregation State and Neurotoxic Properties of Alzheimer β-Amyloid Peptide. <i>Current Protein and Peptide Science</i> , 2011, 12, 235-257.	0.7	20
68	Dysregulated phosphorylation of Ca ²⁺ /calmodulin-dependent protein kinase II β in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2011, 119, 791-804.	2.1	91
69	Role of presenilin1 in structural plasticity of cortical dendritic spines <i>in vivo</i> . <i>Journal of Neurochemistry</i> , 2011, 119, 1064-1073.	2.1	18
70	Caspase activation without apoptosis: insight into A β initiation of neurodegeneration. <i>Nature Neuroscience</i> , 2011, 14, 5-6.	7.1	38
71	Orphan nuclear receptors control neuronal remodeling during fly metamorphosis. <i>Nature Neuroscience</i> , 2011, 14, 6-7.	7.1	11
72	Extracellular phosphorylation of the amyloid β -peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. <i>EMBO Journal</i> , 2011, 30, 2255-2265.	3.5	160
73	Deposition of Hyperphosphorylated Tau in Cerebellum of PS1 E280A Alzheimer's Disease. <i>Brain Pathology</i> , 2011, 21, 452-463.	2.1	65
74	Up-regulation of calyntenin-3 by β -amyloid increases vulnerability of cortical neurons. <i>FEBS Letters</i> , 2011, 585, 651-656.	1.3	17
75	CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. <i>Integrative Biology (United Kingdom)</i> , 2011, 3, 1188-1196.	0.6	72

#	ARTICLE	IF	CITATIONS
76	Alzheimer's Disease: The Challenge of the Second Century. <i>Science Translational Medicine</i> , 2011, 3, 77sr1.	5.8	1,109
77	A β Oligomer-Induced Synapse Degeneration in Alzheimer's Disease. <i>Cellular and Molecular Neurobiology</i> , 2011, 31, 939-948.	1.7	144
78	Nicotine Decreases Beta-Amyloid Through Regulating BACE1 Transcription in SH-EP1- β 42 nAChR-APP695 Cells. <i>Neurochemical Research</i> , 2011, 36, 904-912.	1.6	10
79	In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. <i>Acta Neuropathologica</i> , 2011, 121, 327-335.	3.9	86
80	Early calcium dysregulation in Alzheimer's disease: setting the stage for synaptic dysfunction. <i>Science China Life Sciences</i> , 2011, 54, 752-762.	2.3	59
81	Alzheimer's disease: synapses gone cold. <i>Molecular Neurodegeneration</i> , 2011, 6, 63.	4.4	250
82	Amyloid beta protein-induced zinc sequestration leads to synaptic loss via dysregulation of the ProSAP2/Shank3 scaffold. <i>Molecular Neurodegeneration</i> , 2011, 6, 65.	4.4	66
83	Quantitative analysis of glutamatergic innervation of the mouse dorsal raphe nucleus using array tomography. <i>Journal of Comparative Neurology</i> , 2011, 519, 3802-3814.	0.9	31
84	Predicting MCI outcome with clinically available MRI and CSF biomarkers. <i>Neurology</i> , 2011, 77, 1619-1628.	1.5	179
85	Intrahippocampal Amyloid- β (1-40) Injections Injure Medial Septal Neurons in Rats. <i>Current Alzheimer Research</i> , 2011, 8, 832-840.	0.7	20
86	Sequestration of Toxic Oligomers by HspB1 as a Cytoprotective Mechanism. <i>Molecular and Cellular Biology</i> , 2011, 31, 3146-3157.	1.1	83
87	Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease. <i>Archives of Neurology</i> , 2011, 68, 1062.	4.9	173
88	β -secretase inhibitors for treating Alzheimer's disease: rationale and clinical data. <i>Clinical Investigation</i> , 2011, 1, 1175-1194.	0.0	2
89	Alzheimer's Disease. <i>Cold Spring Harbor Perspectives in Biology</i> , 2011, 3, a004457-a004457.	2.3	348
90	Characterization of Oligomer Formation of Amyloid- β Peptide Using a Split-luciferase Complementation Assay. <i>Journal of Biological Chemistry</i> , 2011, 286, 27081-27091.	1.6	65
91	Alzheimer's Disease: Pathological Mechanisms and Recent Insights. <i>Current Neuropharmacology</i> , 2011, 9, 674-684.	1.4	46
92	Dynamic Analysis of Amyloid- β -Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal A β during Age-Related Plaque Formation. <i>Journal of Neuroscience</i> , 2011, 31, 15861-15869.	1.7	95
93	Critical Role of Astroglial Apolipoprotein E and Liver X Receptor- β Expression for Microglial A β Phagocytosis. <i>Journal of Neuroscience</i> , 2011, 31, 7049-7059.	1.7	163

#	ARTICLE	IF	CITATIONS
94	Microglial P2X ₇ receptor expression is accompanied by neuronal damage in the cerebral cortex of the APP ^{swe} /PS1 ^{dE9} mouse model of Alzheimer's disease. <i>Experimental and Molecular Medicine</i> , 2011, 43, 7.	3.2	83
95	Synapses and Alzheimer's Disease. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a005777-a005777.	2.3	340
96	Region-Specific Hierarchy between Atrophy, Hypometabolism, and β -Amyloid (A β) Load in Alzheimer's Disease Dementia. <i>Journal of Neuroscience</i> , 2012, 32, 16265-16273.	1.7	319
97	Biochemistry of Amyloid β -Protein and Amyloid Deposits in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006262-a006262.	2.9	451
98	Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid- β . <i>Brain</i> , 2012, 135, 2155-2168.	3.7	268
99	Differing Effects of Toxicants (Methylmercury, Inorganic Mercury, Lead, Amyloid β , and Rotenone) on Cultured Rat Cerebrocortical Neurons: Differential Expression of Rho Proteins Associated With Neurotoxicity. <i>Toxicological Sciences</i> , 2012, 126, 506-514.	1.4	43
100	Membrane lipid composition and its physicochemical properties define cell vulnerability to aberrant protein oligomers. <i>Journal of Cell Science</i> , 2012, 125, 2416-27.	1.2	75
101	C-terminal fragment of N-cadherin accelerates synapse destabilization by amyloid- β . <i>Brain</i> , 2012, 135, 2140-2154.	3.7	45
102	Cdk5 Protein Inhibition and A β ₄₂ Increase BACE1 Protein Level in Primary Neurons by a Post-transcriptional Mechanism. <i>Journal of Biological Chemistry</i> , 2012, 287, 7224-7235.	1.6	56
103	Immunotherapy for Alzheimer's disease: from anti- β -amyloid to tau-based immunization strategies. <i>Immunotherapy</i> , 2012, 4, 213-238.	1.0	121
104	Spines, Plasticity, and Cognition in Alzheimer's Model Mice. <i>Neural Plasticity</i> , 2012, 2012, 1-10.	1.0	117
105	Stable Size Distribution of Amyloid Plaques Over the Course of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 694-701.	0.9	41
106	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 362-381.	0.9	1,599
107	A Plaque-Specific Antibody Clears Existing β -amyloid Plaques in Alzheimer's Disease Mice. <i>Neuron</i> , 2012, 76, 908-920.	3.8	259
108	Amyloid plaque formation precedes dendritic spine loss. <i>Acta Neuropathologica</i> , 2012, 124, 797-807.	3.9	77
110	Neurotoxicity of Amyloid β -Protein: Synaptic and Network Dysfunction. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006338-a006338.	2.9	844
111	Mechanistic involvement of the calpain-calcipastatin system in Alzheimer neuropathology. <i>FASEB Journal</i> , 2012, 26, 1204-1217.	0.2	82
112	Curcumin-Mediated Neuroprotection Against Amyloid- β -Induced Mitochondrial Dysfunction Involves the Inhibition of GSK-3 β . <i>Journal of Alzheimer's Disease</i> , 2012, 32, 981-996.	1.2	83

#	ARTICLE	IF	CITATIONS
113	CB1 Cannabinoid Receptor Activation Rescues Amyloid A β -Induced Alterations in Behaviour and Intrinsic Electrophysiological Properties of Rat Hippocampal CA1 Pyramidal Neurones. <i>Cellular Physiology and Biochemistry</i> , 2012, 29, 391-406.	1.1	77
114	Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 198.e1-198.e14.	1.5	135
115	Different A β -amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. <i>Neurobiology of Aging</i> , 2012, 33, 825.e1-825.e13.	1.5	86
116	AD synapses contain abundant A β monomer and multiple soluble oligomers, including a 56-kDa assembly. <i>Neurobiology of Aging</i> , 2012, 33, 1545-1555.	1.5	54
117	A β -Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis. <i>Neurobiology of Aging</i> , 2012, 33, 2807-2816.	1.5	40
118	Propagation of Tau Pathology in a Model of Early Alzheimer's Disease. <i>Neuron</i> , 2012, 73, 685-697.	3.8	1,191
119	Remodeling of synapses in the CA1 area of the hippocampus after transient global ischemia. <i>Neuroscience</i> , 2012, 218, 268-277.	1.1	30
120	A β alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo. <i>Nature Communications</i> , 2012, 3, 1009.	5.8	71
121	Structure and Dynamics of Small Soluble A β (1-40) Oligomers Studied by Top-Down Hydrogen Exchange Mass Spectrometry. <i>Biochemistry</i> , 2012, 51, 3694-3703.	1.2	64
122	Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid A β Peptide. <i>Journal of Neuroscience</i> , 2012, 32, 15181-15192.	1.7	219
123	APOE4-specific Changes in A β Accumulation in a New Transgenic Mouse Model of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2012, 287, 41774-41786.	1.6	213
124	Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease. <i>Nature Neuroscience</i> , 2012, 15, 1422-1429.	7.1	108
125	Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease. <i>Nature Communications</i> , 2012, 3, 774.	5.8	116
126	Structural features and cytotoxicity of amyloid oligomers: Implications in Alzheimer's disease and other diseases with amyloid deposits. <i>Progress in Neurobiology</i> , 2012, 99, 226-245.	2.8	154
127	Detection of Peri-Synaptic Amyloid-A β Pyroglutamate Aggregates in Early Stages of Alzheimer's Disease and in A β PP Transgenic Mice Using a Novel Monoclonal Antibody. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 783-794.	1.2	18
128	Isolated Amyloid-A β (1-42) Protofibrils, But Not Isolated Fibrils, Are Robust Stimulators of Microglia. <i>ACS Chemical Neuroscience</i> , 2012, 3, 302-311.	1.7	62
129	The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-A β 1-40 peptide. <i>Nature Structural and Molecular Biology</i> , 2012, 19, 79-83.	3.6	232
130	Absence of amyloid A β oligomers at the postsynapse and regulated synaptic Zn ²⁺ in cognitively intact aged individuals with Alzheimer's disease neuropathology. <i>Molecular Neurodegeneration</i> , 2012, 7, 23.	4.4	72

#	ARTICLE	IF	CITATIONS
131	The Relationship between Aggregation and Toxicity of Polyglutamine-Containing Ataxin-3 in the Intracellular Environment of Escherichia coli. <i>PLoS ONE</i> , 2012, 7, e51890.	1.1	20
132	A Peephole into the Brain: Neuropathological Features of Alzheimer's Disease Revealed by in vivo Two-Photon Imaging. <i>Frontiers in Psychiatry</i> , 2012, 3, 26.	1.3	29
133	Inhibition of the NFAT Pathway Alleviates Amyloid Beta Neurotoxicity in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 3176-3192.	1.7	92
134	The Complement System: An Unexpected Role in Synaptic Pruning During Development and Disease. <i>Annual Review of Neuroscience</i> , 2012, 35, 369-389.	5.0	876
135	Protein Misfolded Oligomers: Experimental Approaches, Mechanism of Formation, and Structure-Toxicity Relationships. <i>Chemistry and Biology</i> , 2012, 19, 315-327.	6.2	239
136	Activation of glycogen synthase kinase-3 beta mediates β -amyloid induced neuritic damage in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2012, 45, 425-437.	2.1	145
137	Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APP ^{swe} /PS1 ^{dE9} transgenic mice. <i>Journal of Neuroscience Research</i> , 2012, 90, 508-517.	1.3	47
138	Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer's mice hippocampus. <i>Acta Neuropathologica</i> , 2012, 123, 53-70.	3.9	179
139	Protective effects of bilobalide on $A\beta_{25-35}$ induced learning and memory impairments in male rats. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 106, 77-84.	1.3	47
140	Neurogenic effects of β -amyloid in the choroid plexus epithelial cells in Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 2787-2797.	2.4	17
141	Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2013, 1828, 2532-2543.	1.4	120
142	The case for soluble $A\beta$ oligomers as a drug target in Alzheimer's disease. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 261-266.	4.0	102
143	Studying synapses in human brain with array tomography and electron microscopy. <i>Nature Protocols</i> , 2013, 8, 1366-1380.	5.5	95
144	Effects of corticosterone and amyloid-beta on proteins essential for synaptic function: Implications for depression and Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 2245-2256.	1.8	35
145	Neurotoxic Saboteurs: Straws that Break the Hippocampus (Hippocampus) Back Drive Cognitive Impairment and Alzheimer's Disease. <i>Neurotoxicity Research</i> , 2013, 24, 407-459.	1.3	47
146	Reversal of Neurofibrillary Tangles and Tau-Associated Phenotype in the rTgTauEC Model of Early Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2013, 33, 13300-13311.	1.7	42
147	Clustering of plaques contributes to plaque growth in a mouse model of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2013, 126, 179-188.	3.9	27
148	β -amyloid and ATP-induced diffusional trapping of astrocyte and neuronal metabotropic glutamate type-5 receptors. <i>Glia</i> , 2013, 61, 1673-1686.	2.5	80

#	ARTICLE	IF	CITATIONS
149	A new fluorescent probe for monitoring amyloid fibrillation with high sensitivity and reliability. <i>RSC Advances</i> , 2013, 3, 21092.	1.7	19
150	Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. <i>Brain</i> , 2013, 136, 2510-2526.	3.7	294
151	Curcumin protects organotypic hippocampal slice cultures from A β 42-induced synaptic toxicity. <i>Toxicology in Vitro</i> , 2013, 27, 2325-2330.	1.1	33
152	Proliferation of amyloid- β 42 aggregates occurs through a secondary nucleation mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9758-9763.	3.3	1,162
153	Protein Folding and Aggregation into Amyloid: The Interference by Natural Phenolic Compounds. <i>International Journal of Molecular Sciences</i> , 2013, 14, 12411-12457.	1.8	180
154	Gene Transfer of Human ApoE Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain. <i>Science Translational Medicine</i> , 2013, 5, 212ra161.	5.8	135
155	Mitochondrial Alterations near Amyloid Plaques in an Alzheimer's Disease Mouse Model. <i>Journal of Neuroscience</i> , 2013, 33, 17042-17051.	1.7	156
156	Single-Molecule Imaging Reveals A β 42:A β 40 Ratio-Dependent Oligomer Growth on Neuronal Processes. <i>Biophysical Journal</i> , 2013, 104, 894-903.	0.2	29
157	Modulation of the stability of amyloidogenic precursors by anion binding strongly influences the rate of amyloid nucleation. <i>Physical Chemistry Chemical Physics</i> , 2013, 15, 15508.	1.3	17
158	Combination therapy in a transgenic model of Alzheimer's disease. <i>Experimental Neurology</i> , 2013, 250, 228-238.	2.0	29
159	Tau-amyloid interactions in the rTgTauEC model of early Alzheimer's disease suggest amyloid-induced disruption of axonal projections and exacerbated axonal pathology. <i>Journal of Comparative Neurology</i> , 2013, 521, 4236-4248.	0.9	28
160	In vivo modification of A β plaque toxicity as a novel neuroprotective lithium-mediated therapy for Alzheimer's disease pathology. <i>Acta Neuropathologica Communications</i> , 2013, 1, 73.	2.4	33
161	Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. <i>Neurobiology of Aging</i> , 2013, 34, 822-831.	1.5	118
162	Scaffolding Proteins of the Post-synaptic Density Contribute to Synaptic Plasticity by Regulating Receptor Localization and Distribution: Relevance for Neuropsychiatric Diseases. <i>Neurochemical Research</i> , 2013, 38, 1-22.	1.6	70
163	Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2013, 125, 187-199.	3.9	67
164	Amyloid- β oligomer detection by ELISA in cerebrospinal fluid and brain tissue. <i>Analytical Biochemistry</i> , 2013, 433, 112-120.	1.1	103
165	Enhancement of long-term depression by soluble amyloid β protein in rat hippocampus is mediated by metabotropic glutamate receptor and involves activation of p38MAPK, STEP and caspase-3. <i>Neuroscience</i> , 2013, 253, 435-443.	1.1	75
166	Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease. , 2013, 9, 459-462.		13

#	ARTICLE	IF	CITATIONS
167	New nicotinic analogue ZY-1 enhances cognitive functions in a transgenic mice model of Alzheimer's disease. <i>Neuroscience Letters</i> , 2013, 537, 29-34.	1.0	20
168	The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. <i>Ageing Research Reviews</i> , 2013, 12, 757-763.	5.0	130
169	Synaptic alterations in the rTg4510 mouse model of tauopathy. <i>Journal of Comparative Neurology</i> , 2013, 521, 1334-1353.	0.9	98
170	Amyloidogenesis, Neurogenesis, Learning, and Memory in Alzheimer's Disease: Lessons from Transgenic Mouse Models. <i>Molecular Medicine and Biotechnology</i> , 2013, , 157-186.	0.4	0
171	New ELISAs with high specificity for soluble oligomers of amyloid β protein detect natural $A\beta$ oligomers in human brain but not CSF. <i>Alzheimer's and Dementia</i> , 2013, 9, 99-112.	0.4	103
175	Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. <i>FASEB Journal</i> , 2013, 27, 3239-3248.	0.2	57
176	The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity. <i>Biophysical Chemistry</i> , 2013, 182, 30-43.	1.5	96
177	The Structural Basis for Optimal Performance of Oligothiophene-Based Fluorescent Amyloid Ligands: Conformational Flexibility is Essential for Spectral Assignment of a Diversity of Protein Aggregates. <i>Chemistry - A European Journal</i> , 2013, 19, 10179-10192.	1.7	95
178	Brain regional correlation of amyloid- β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid- β accumulation. <i>Acta Neuropathologica</i> , 2013, 125, 535-547.	3.9	51
179	Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2540-2545.	3.3	75
180	Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. <i>Psychoneuroendocrinology</i> , 2013, 38, 2462-2475.	1.3	118
181	Characterization of Myelin Pathology in the Hippocampal Complex of a Transgenic Mouse Model of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2013, 10, 30-37.	0.7	1
182	An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment. <i>American Journal of Neuroradiology</i> , 2013, 34, 2075-2082.	1.2	24
183	Examination of the Clinicopathologic Continuum of Alzheimer Disease in the Autopsy Cohort of the National Alzheimer Coordinating Center. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 1182-1192.	0.9	89
184	Dendritic Spine Density, Morphology, and Fibrillar Actin Content Surrounding Amyloid- β Plaques in a Mouse Model of Amyloid- β Deposition. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 791-800.	0.9	33
185	Amyloid imaging in dementia. <i>Reviews in Clinical Gerontology</i> , 2013, 23, 43-60.	0.5	0
186	Expanding the Repertoire of Amyloid Polymorphs by Co-polymerization of Related Protein Precursors. <i>Journal of Biological Chemistry</i> , 2013, 288, 7327-7337.	1.6	36
187	Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders. <i>Journal of Neurochemistry</i> , 2013, 126, 165-182.	2.1	106

#	ARTICLE	IF	CITATIONS
188	Operational dissection of $A\beta$ amyloid cytopathic effects on cultured neurons. <i>Journal of Neuroscience Research</i> , 2013, 91, 706-716.	1.3	22
189	Amyloid β oligomerization in Alzheimer dementia versus high β pathology controls. <i>Annals of Neurology</i> , 2013, 73, 104-119.	2.8	244
190	Rapid cell death is preceded by amyloid plaque-mediated oxidative stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7904-7909.	3.3	139
191	Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR by shRNAs rescue cells from $A\beta$ 242 induced cytotoxicity. <i>Scientific Reports</i> , 2013, 3, 2702.	1.6	23
192	Differential Relationships of Reactive Astrocytes and Microglia to Fibrillar Amyloid Deposits in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 462-471.	0.9	163
193	What can we learn from regional vulnerability to amyloid- β accumulation in nondemented individuals?. <i>Neurodegenerative Disease Management</i> , 2013, 3, 187-189.	1.2	2
194	FIB/SEM Technology and Alzheimer's Disease: Three-Dimensional Analysis of Human Cortical Synapses. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 995-1013.	1.2	52
195	Specific Uptake of an Amyloid- β Protofibril-Binding Antibody-Tracer in $A\beta$ PP Transgenic Mouse Brain. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 29-40.	1.2	65
196	Increased Tau Phosphorylation and Tau Truncation, and Decreased Synaptophysin Levels in Mutant BRL2/Tau Transgenic Mice. <i>PLoS ONE</i> , 2013, 8, e56426.	1.1	18
197	Neurites containing the neurofilament-triplet proteins are selectively vulnerable to cytoskeletal pathology in Alzheimer's disease and transgenic mouse models. <i>Frontiers in Neuroanatomy</i> , 2013, 7, 30.	0.9	25
198	RNA Aptamer Probes as Optical Imaging Agents for the Detection of Amyloid Plaques. <i>PLoS ONE</i> , 2014, 9, e89901.	1.1	37
199	Genetic Inhibition of Phosphorylation of the Translation Initiation Factor eIF2 β Does Not Block $A\beta$ -Dependent Elevation of BACE1 and APP Levels or Reduce Amyloid Pathology in a Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e101643.	1.1	31
200	Alzheimer's Therapeutics Targeting Amyloid Beta 1-42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity. <i>PLoS ONE</i> , 2014, 9, e111899.	1.1	151
201	Unraveling the architecture of the dorsal raphe synaptic neuropil using high-resolution neuroanatomy. <i>Frontiers in Neural Circuits</i> , 2014, 8, 105.	1.4	35
202	Pathological Reorganization of NMDA Receptors Subunits and Postsynaptic Protein PSD-95 Distribution in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2014, 11, 86-96.	0.7	31
203	Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 759-773.	1.2	46
204	Neuronal Impulse Theory and Alzheimer's Disease. , 2014, 04, .		1
205	Models of β -amyloid induced Tau-pathology: the long and β -folded road to understand the mechanism. <i>Molecular Neurodegeneration</i> , 2014, 9, 51.	4.4	220

#	ARTICLE	IF	CITATIONS
206	Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 9959-9964.	3.3	162
207	Chronic β -secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures. <i>Molecular Psychiatry</i> , 2014, 19, 937-946.	4.1	38
208	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 405-419.	1.3	86
209	Potential Therapeutic Strategies for Alzheimer's Disease Targeting or Beyond β -Amyloid: Insights from Clinical Trials. <i>BioMed Research International</i> , 2014, 2014, 1-22.	0.9	61
210	Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model. <i>Brain</i> , 2014, 137, 3319-3326.	3.7	36
211	Platelet-Activating Factor Mediates the Cytotoxicity Induced by W7FW14F Apomyoglobin Amyloid Aggregates in Neuroblastoma Cells. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 2116-2122.	1.2	8
212	Genetic Modulation of Soluble A β Rescues Cognitive and Synaptic Impairment in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2014, 34, 7871-7885.	1.7	74
213	Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. <i>Current Opinion in Psychiatry</i> , 2014, 27, 128-137.	3.1	86
214	A Death Receptor 6-Amyloid Precursor Protein Pathway Regulates Synapse Density in the Mature CNS But Does Not Contribute to Alzheimer's Disease-Related Pathophysiology in Murine Models. <i>Journal of Neuroscience</i> , 2014, 34, 6425-6437.	1.7	48
215	Analyzing Alzheimer's Disease-Related Protein Deposition In Vivo By Multiphoton Laser Scanning Microscopy. , 2014, , 97-104.		0
216	Targeting mRNA for Alzheimer's and Related Dementias. <i>Scientifica</i> , 2014, 2014, 1-13.	0.6	10
217	Simultaneous Changes of Spatial Memory and Spine Density after Intrahippocampal Administration of Fibrillar A β ₁₋₄₂ to the Rat Brain. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	17
218	Impairment of in vivo calcium signaling in amyloid plaque-associated microglia. <i>Acta Neuropathologica</i> , 2014, 127, 495-505.	3.9	88
219	Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. <i>Biochemical Pharmacology</i> , 2014, 88, 468-478.	2.0	93
220	Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. <i>Biochemical Pharmacology</i> , 2014, 88, 508-516.	2.0	196
221	Impairments in experience-dependent scaling and stability of hippocampal place fields limit spatial learning in a mouse model of Alzheimer's disease. <i>Hippocampus</i> , 2014, 24, 963-978.	0.9	33
222	The amyloid state and its association with protein misfolding diseases. <i>Nature Reviews Molecular Cell Biology</i> , 2014, 15, 384-396.	16.1	1,894
223	Amyloid Aggregation: Role of Biological Membranes and the Aggregate-Membrane System. <i>Journal of Physical Chemistry Letters</i> , 2014, 5, 517-527.	2.1	88

#	ARTICLE	IF	CITATIONS
224	Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. <i>Neurobiology of Aging</i> , 2014, 35, 969-974.	1.5	119
225	Amyloid- β^2 Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo. <i>Journal of Biological Chemistry</i> , 2014, 289, 30538-30555.	1.6	82
226	Biochemical and immunological aspects of protein aggregation in neurodegenerative diseases. <i>Journal of the Iranian Chemical Society</i> , 2014, 11, 1503-1512.	1.2	3
228	Inhibiting ACAT1/SOAT1 in Microglia Stimulates Autophagy-Mediated Lysosomal Proteolysis and Increases A β^{1-42} Clearance. <i>Journal of Neuroscience</i> , 2014, 34, 14484-14501.	1.7	86
229	Brilliant Blue G improves cognition in an animal model of Alzheimer's disease and inhibits amyloid- β^2 -induced loss of filopodia and dendrite spines in hippocampal neurons. <i>Neuroscience</i> , 2014, 279, 94-101.	1.1	76
230	Prediabetes-induced vascular alterations exacerbate central pathology in APP ^{swe} /PS1 ^{dE9} mice. <i>Psychoneuroendocrinology</i> , 2014, 48, 123-135.	1.3	54
231	Leptin gene therapy attenuates neuronal damages evoked by amyloid- β^2 and rescues memory deficits in APP/PS1 mice. <i>Gene Therapy</i> , 2014, 21, 298-308.	2.3	64
232	Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 42.	3.0	140
233	Transient dynamics of A β^2 contribute to toxicity in Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 3507-3521.	2.4	76
234	Diagnostic effectiveness of quantitative [18F]flutemetamol PET imaging for detection of fibrillar amyloid β^2 using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. <i>Acta Neuropathologica Communications</i> , 2014, 2, 46.	2.4	19
235	A role for the neurexin-neuroigin complex in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 746-756.	1.5	42
236	Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1465-1476.	1.4	63
237	Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. <i>Brain</i> , 2014, 137, 1533-1549.	3.7	100
238	Physicochemical Properties of Cells and Their Effects on Intrinsically Disordered Proteins (IDPs). <i>Chemical Reviews</i> , 2014, 114, 6661-6714.	23.0	391
239	β^2 -Asarone prevents autophagy and synaptic loss by reducing ROCK expression in senescence-accelerated prone 8 mice. <i>Brain Research</i> , 2014, 1552, 41-54.	1.1	34
240	Decreased rabphilin 3A immunoreactivity in Alzheimer's disease is associated with A β^2 burden. <i>Neurochemistry International</i> , 2014, 64, 29-36.	1.9	41
241	Amyloid- β^2 alters ongoing neuronal activity and excitability in the frontal cortex. <i>Neurobiology of Aging</i> , 2014, 35, 1982-1991.	1.5	34
242	Disrupted cross-laminar cortical processing in β^2 amyloid pathology precedes cell death. <i>Neurobiology of Disease</i> , 2014, 63, 62-73.	2.1	21

#	ARTICLE	IF	CITATIONS
243	Glial Calcium Signalling in Alzheimer's Disease. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2014, 167, 45-65.	0.9	57
244	The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer's Disease. <i>Neuron</i> , 2014, 82, 756-771.	3.8	862
245	Synaptophysin and Synaptotagmin-1 in Down Syndrome are Differentially Affected by Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 767-775.	1.2	46
246	Plaque-associated lipids in Alzheimer's diseased brain tissue visualized by nonlinear microscopy. <i>Scientific Reports</i> , 2015, 5, 13489.	1.6	86
247	Prion-Protein-interacting Amyloid- β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. <i>Journal of Biological Chemistry</i> , 2015, 290, 17415-17438.	1.6	104
248	Limited Proteolysis Reveals That Amyloids from the 3D Domain-Swapping Cystatin B Have a Non-Native β -Sheet Topology. <i>Journal of Molecular Biology</i> , 2015, 427, 2418-2434.	2.0	10
249	Blood-Brain Barrier Damage and Dysfunction by Chemical Toxicity. , 2015, , 725-739.		2
250	Topological analyses in APP/PS1 mice reveal that astrocytes do not migrate to amyloid- β plaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15556-15561.	3.3	39
251	Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APP ^{swe} /PS1 ^{dE9} mice. <i>Acta Neuropathologica Communications</i> , 2015, 3, 54.	2.4	38
252	Array tomography for the detection of non-dilated, injured axons in traumatic brain injury. <i>Journal of Neuroscience Methods</i> , 2015, 245, 25-36.	1.3	12
253	A Food and Drug Administration-approved Asthma Therapeutic Agent Impacts Amyloid β in the Brain in a Transgenic Model of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2015, 290, 1966-1978.	1.6	65
254	Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. <i>Acta Neuropathologica</i> , 2015, 129, 183-206.	3.9	490
255	Viral capsid assembly as a model for protein aggregation diseases: Active processes catalyzed by cellular assembly machines comprising novel drug targets. <i>Virus Research</i> , 2015, 207, 155-164.	1.1	16
256	The pathophysiology of repetitive concussive traumatic brain injury in experimental models; new developments and open questions. <i>Molecular and Cellular Neurosciences</i> , 2015, 66, 91-98.	1.0	45
257	Soluble amyloid- β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 191.	1.8	284
258	Chemical Fluorescent Probe for Detection of β Oligomers. <i>Journal of the American Chemical Society</i> , 2015, 137, 13503-13509.	6.6	163
259	DHA-PC and PSD-95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer's disease. <i>Scientific Reports</i> , 2014, 4, 7130.	1.6	135
260	Analyzing dendritic spine pathology in Alzheimer's disease: problems and opportunities. <i>Acta Neuropathologica</i> , 2015, 130, 1-19.	3.9	154

#	ARTICLE	IF	CITATIONS
261	Olive Oil Phenols as Promising Multi-targeting Agents Against Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2015, 863, 1-20.	0.8	62
262	Intraventricular Delivery of siRNA Nanoparticles to the Central Nervous System. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e242.	2.3	43
263	Neuronal hyperactivity "A key defect in Alzheimer's disease?". <i>BioEssays</i> , 2015, 37, 624-632.	1.2	182
264	Alzheimer's Disease and Mechanism-Based Attempts to Enhance Cognition. , 2015, , 193-231.		0
265	Hippocampal plasticity during the progression of Alzheimer's disease. <i>Neuroscience</i> , 2015, 309, 51-67.	1.1	120
266	Amyloid Fibres: Inert End-Stage Aggregates or Key Players in Disease?. <i>Trends in Biochemical Sciences</i> , 2015, 40, 719-727.	3.7	100
267	Biodegradable Polymer Nanogels for Drug/Nucleic Acid Delivery. <i>Chemical Reviews</i> , 2015, 115, 8564-8608.	23.0	401
268	The combined treatment of amyloid- β 1-42-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APP ^{swe} /PSEN1 ^{dE9} mice. <i>Neurobiology of Aging</i> , 2015, 36, 111-122.	1.5	17
269	Evidence for Alzheimer's disease-linked synapse loss and compensation in mouse and human hippocampal CA1 pyramidal neurons. <i>Brain Structure and Function</i> , 2015, 220, 3143-3165.	1.2	83
270	Interrelationship between Changes in the Amyloid β 42/40 Ratio and Presenilin 1 Conformation. <i>Molecular Medicine</i> , 2016, 22, 329-337.	1.9	20
271	First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 169-176.	1.8	113
272	Early Activation of Experience-Independent Dendritic Spine Turnover in a Mouse Model of Alzheimer's Disease. <i>Cerebral Cortex</i> , 2016, 27, 3660-3674.	1.6	20
273	Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid- β B-cell epitope chimeric protein as subunit vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2801-2804.	1.4	8
274	Impairments of neural circuit function in Alzheimer's disease. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2016, 371, 20150429.	1.8	241
275	Sensorimotor cortex excitability and connectivity in Alzheimer's disease: A TMS-EEG Co-registration study. <i>Human Brain Mapping</i> , 2016, 37, 2083-2096.	1.9	84
276	Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 24939.	1.6	92
277	Aberrant Co-localization of Synaptic Proteins Promoted by Alzheimer's Disease Amyloid- β Peptides: Protective Effect of Human Serum Albumin. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 171-182.	1.2	18
278	Molecular evidence of synaptic pathology in the CA1 region in schizophrenia. <i>NPJ Schizophrenia</i> , 2016, 2, 16022.	2.0	62

#	ARTICLE	IF	CITATIONS
279	The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease. <i>Behavioural Brain Research</i> , 2016, 311, 309-321.	1.2	78
280	Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A β generation in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2016, 132, 235-256.	3.9	193
281	A β 1-42-induced dysfunction in synchronized gamma oscillation during working memory. <i>Behavioural Brain Research</i> , 2016, 307, 112-119.	1.2	13
282	Real-time characterization of fibrillization process of amyloid-beta on phospholipid membrane using a new label-free detection technique based on a cantilever-based liposome biosensor. <i>Sensors and Actuators B: Chemical</i> , 2016, 236, 893-899.	4.0	13
283	Amyloid-beta oligomerization is associated with the generation of a typical peptide fragment fingerprint. <i>Alzheimer's and Dementia</i> , 2016, 12, 996-1013.	0.4	17
284	Synaptic pathology: A shared mechanism in neurological disease. <i>Ageing Research Reviews</i> , 2016, 28, 72-84.	5.0	122
285	Emerging drugs to reduce abnormal β -amyloid protein in Alzheimer's disease patients. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 377-391.	1.0	54
286	SNX27 and SORLA Interact to Reduce Amyloidogenic Subcellular Distribution and Processing of Amyloid Precursor Protein. <i>Journal of Neuroscience</i> , 2016, 36, 7996-8011.	1.7	44
287	The antibody aducanumab reduces A β plaques in Alzheimer's disease. <i>Nature</i> , 2016, 537, 50-56.	13.7	2,179
288	Amyloid- β 242 protofibrils are internalized by microglia more extensively than monomers. <i>Brain Research</i> , 2016, 1648, 485-495.	1.1	26
289	The amyloid hypothesis of Alzheimer's disease at 25 years. <i>EMBO Molecular Medicine</i> , 2016, 8, 595-608.	3.3	4,226
290	Non-Fibrillar Oligomeric Amyloid- β within Synapses. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 787-800.	1.2	65
291	Trifluoroethanol modulates α -synuclein amyloid-like aggregate formation, stability and dissolution. <i>Biophysical Chemistry</i> , 2016, 216, 23-30.	1.5	9
292	Network abnormalities and interneuron dysfunction in Alzheimer disease. <i>Nature Reviews Neuroscience</i> , 2016, 17, 777-792.	4.9	685
293	Depletion of TDP-43 decreases fibril and plaque β -amyloid and exacerbates neurodegeneration in an Alzheimer's mouse model. <i>Acta Neuropathologica</i> , 2016, 132, 859-873.	3.9	43
294	HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 31895.	1.6	111
295	Human tau increases amyloid β plaque size but not amyloid β -mediated synapse loss in a novel mouse model of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2016, 44, 3056-3066.	1.2	81
296	Prospects and Challenges for Alzheimer Therapeutics. , 2016, , 605-637.		2

#	ARTICLE	IF	CITATIONS
297	Identification of the novel activity-driven interaction between synaptotagmin 1 and presenilin 1 links calcium, synapse, and amyloid beta. <i>BMC Biology</i> , 2016, 14, 25.	1.7	33
298	Heparan sulfate proteoglycans mediate A β -induced oxidative stress and hypercontractility in cultured vascular smooth muscle cells. <i>Molecular Neurodegeneration</i> , 2016, 11, 9.	4.4	25
299	Oligomers of Amyloid β Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2016, 291, 17112-17121.	1.6	65
300	Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids. <i>ACS Chemical Neuroscience</i> , 2016, 7, 399-406.	1.7	99
301	Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease. <i>Progress in Neurobiology</i> , 2016, 144, 121-141.	2.8	238
302	Amyloid Plaque-Associated Oxidative Degradation of Uniformly Radiolabeled Arachidonic Acid. <i>ACS Chemical Neuroscience</i> , 2016, 7, 367-377.	1.7	22
304	A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. <i>Nature Reviews Neuroscience</i> , 2016, 17, 251-260.	4.9	251
305	Neurotrophic activity of jiadifenolide on neuronal precursor cells derived from human induced pluripotent stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 470, 798-803.	1.0	16
306	Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease. <i>Nature Communications</i> , 2016, 7, 10759.	5.8	155
307	Dendritic Spine Pathology in Neurodegenerative Diseases. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 221-250.	9.6	161
308	The Luminescent Oligothiophene p-FTAA Converts Toxic A β 1-42 Species into Nontoxic Amyloid Fibers with Altered Properties. <i>Journal of Biological Chemistry</i> , 2016, 291, 9233-9243.	1.6	17
309	Alzheimer's Disease and the Sleep-Wake Cycle. , 2016, , 295-317.		0
310	Peripherally administered sera antibodies recognizing amyloid- β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3 \times -Tg-AD mice. <i>Vaccine</i> , 2016, 34, 1758-1766.	1.7	11
311	Potential Animal Models of Alzheimer Disease and Their Importance in Investigating the Pathogenesis of Alzheimer Disease. , 2016, , 77-111.		0
312	Synaptic Amyloid- β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases. <i>American Journal of Pathology</i> , 2016, 186, 185-198.	1.9	94
313	The Essential Role of Soluble A β Oligomers in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016, 53, 1905-1924.	1.9	73
314	Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 47-57.	1.4	65
315	Progressive Neuronal Pathology and Synaptic Loss Induced by Prediabetes and Type 2 Diabetes in a Mouse Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2017, 54, 3428-3438.	1.9	50

#	ARTICLE	IF	CITATIONS
316	Quantitative Comparison of Dense-Core Amyloid Plaque Accumulation in Amyloid- β Protein Precursor Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 743-761.	1.2	39
317	Investigation of the Subcellular Neurotoxicity of Amyloid- β Using a Device Integrating Microfluidic Perfusion and Chemotactic Guidance. <i>Advanced Healthcare Materials</i> , 2017, 6, 1600895.	3.9	16
318	Recent Progress in Alzheimer's Disease Research, Part 1: Pathology. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1-28.	1.2	75
319	Loss of precuneus dendritic spines immunopositive for spinophilin is related to cognitive impairment in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 55, 159-166.	1.5	28
320	High plasticity of axonal pathology in Alzheimer's disease mouse models. <i>Acta Neuropathologica Communications</i> , 2017, 5, 14.	2.4	48
321	Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF- α and IL-1 β in an A β 25-35-induced Rat Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1403-1417.	1.2	18
322	Amyloid-beta peptide decreases expression and function of glutamate transporters in nervous system cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 85, 75-84.	1.2	25
323	Spread of tau down neural circuits precedes synapse and neuronal loss in the rTgTauEC mouse model of early Alzheimer's disease. <i>Synapse</i> , 2017, 71, e21965.	0.6	53
324	Preclinical models of Alzheimer's disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy. , 2017, , 115-156.		2
325	Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. <i>Annual Review of Biochemistry</i> , 2017, 86, 27-68.	5.0	1,929
326	Immunization of Tg-APP ^{swe} /PSEN1 ^{dE9} mice with A β 23-10-KLH vaccine prevents synaptic deficits of Alzheimer's disease. <i>Behavioural Brain Research</i> , 2017, 332, 64-70.	1.2	5
327	Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	401
328	Soluble oligomeric amyloid- β induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. <i>Molecular Neurodegeneration</i> , 2017, 12, 27.	4.4	120
329	Biochemically-defined pools of amyloid- β in sporadic Alzheimer's disease: correlation with amyloid PET. <i>Brain</i> , 2017, 140, 1486-1498.	3.7	123
330	Ion mobility-mass spectrometry and orthogonal gas-phase techniques to study amyloid formation and inhibition. <i>Current Opinion in Structural Biology</i> , 2017, 46, 7-15.	2.6	31
331	Cellular cholesterol homeostasis and Alzheimer's disease. <i>Journal of Lipid Research</i> , 2017, 58, 2239-2254.	2.0	106
332	Concordance of Several Subcellular Interactions Initiates Alzheimer's Dementia: Their Reversal Requires Combination Treatment. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2017, 32, 166-181.	0.9	19
333	Inflammasomes as therapeutic targets for Alzheimer's disease. <i>Brain Pathology</i> , 2017, 27, 223-234.	2.1	110

#	ARTICLE	IF	CITATIONS
334	Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 975-999.	1.2	294
335	Young microglia restore amyloid plaque clearance of aged microglia. <i>EMBO Journal</i> , 2017, 36, 583-603.	3.5	124
336	Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2017, 140, 561-575.	2.1	93
337	Prion-like Protein Seeding and the Pathobiology of Alzheimer's Disease. , 2017, , 57-82.		0
338	Cationization increases brain distribution of an amyloid-beta protofibril selective F(ab') ₂ fragment. <i>Biochemical and Biophysical Research Communications</i> , 2017, 493, 120-125.	1.0	30
339	The conformational epitope for a new A β ₄₂ protofibril-selective antibody partially overlaps with the peptide N-terminal region. <i>Journal of Neurochemistry</i> , 2017, 143, 736-749.	2.1	22
340	BACE inhibition-dependent repair of Alzheimer's pathophysiology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8631-8636.	3.3	93
341	APP/A β structural diversity and Alzheimer's disease pathogenesis. <i>Neurochemistry International</i> , 2017, 110, 1-13.	1.9	78
342	Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	108
343	Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound A β oligomers. <i>Molecular Biology of the Cell</i> , 2017, 28, 2623-2636.	0.9	88
344	An A β ₃₋₁₀ -KLH vaccine reduced Alzheimer's disease-like pathology and had a sustained effect in Tg-APP ^{swe} /PSEN1 ^{dE9} mice. <i>Brain Research</i> , 2017, 1673, 72-77.	1.1	8
345	Human Brain-Derived A β Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP. <i>Journal of Neuroscience</i> , 2017, 37, 11947-11966.	1.7	108
346	Oligomer Formation and Cross-Seeding: The New Frontier. <i>Israel Journal of Chemistry</i> , 2017, 57, 665-673.	1.0	8
347	Long-term depression-associated signaling is required for an in vitro model of NMDA receptor-dependent synapse pruning. <i>Neurobiology of Learning and Memory</i> , 2017, 138, 39-53.	1.0	24
348	Large Soluble Oligomers of Amyloid β -Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. <i>Journal of Neuroscience</i> , 2017, 37, 152-163.	1.7	262
349	Emerging pathways driving early synaptic pathology in Alzheimer's disease. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 988-997.	1.0	69
350	Synaptic phosphorylated τ -synuclein in dementia with Lewy bodies. <i>Brain</i> , 2017, 140, 3204-3214.	3.7	90
351	Perplexity of Amyloid β -Protein Oligomer Formation: Relevance to Alzheimer's Disease. <i>World Scientific Lecture and Course Notes in Chemistry</i> , 2017, , 1-50.	0.2	4

#	ARTICLE	IF	CITATIONS
352	Amyloid β^2 Hypothesis in the Development of Therapeutic Agents for Alzheimer's Disease. , 2017, , 109-143.		5
353	Low-Frequency Repetitive Transcranial Magnetic Stimulation Ameliorates Cognitive Function and Synaptic Plasticity in APP23/PS45 Mouse Model of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 292.	1.7	36
354	The Potential of Small Molecules in Preventing Tau Oligomer Formation and Toxicity. , 2017, , 97-121.		3
355	Pathological Role of Peptidyl-Prolyl Isomerase Pin1 in the Disruption of Synaptic Plasticity in Alzheimer's Disease. <i>Neural Plasticity</i> , 2017, 2017, 1-12.	1.0	28
356	Optogenetic Restoration of Disrupted Slow Oscillations Halts Amyloid Deposition and Restores Calcium Homeostasis in an Animal Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2017, 12, e0170275.	1.1	75
357	Numerical Simulations Reveal Randomness of Cu(II) Induced $A\beta^2$ Peptide Dimerization under Conditions Present in Glutamatergic Synapses. <i>PLoS ONE</i> , 2017, 12, e0170749.	1.1	19
358	Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 62.	3.0	62
359	Molecular Mechanisms of Synaptic Plasticity and Memory and Their Dysfunction in Alzheimer's Disease β^1 . , 2017, , 65-135.		1
360	AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy. <i>Molecular Neurobiology</i> , 2018, 55, 8124-8153.	1.9	16
361	Amyloid- β^2 with isomerized Asp7 cytotoxicity is coupled to protein phosphorylation. <i>Scientific Reports</i> , 2018, 8, 3518.	1.6	24
362	Quantitative Characterization of Metastability and Heterogeneity of Amyloid Aggregates. <i>Biophysical Journal</i> , 2018, 114, 800-811.	0.2	9
363	Evaluation of Congo Red Staining in Degenerating Porcine Photoreceptors In Vitro: Protective Effects by Structural and Trophic Support. <i>Journal of Histochemistry and Cytochemistry</i> , 2018, 66, 631-641.	1.3	3
364	Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5. <i>Advances in Pharmacology</i> , 2018, 82, 293-323.	1.2	67
365	Patrones de retenci3n de 11 C-PIB en la sustancia blanca y en la sustancia gris cerebral de pacientes con hidrocefalia a presi3n normal idiop3tica. Un an3lisis visual. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 87-93.	0.1	0
366	Combination anti- $A\beta^2$ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice. <i>Journal of Experimental Medicine</i> , 2018, 215, 1349-1364.	4.2	14
367	Shedding light on aberrant interactions â€“ a review of modern tools for studying protein aggregates. <i>FEBS Journal</i> , 2018, 285, 3604-3630.	2.2	10
368	Depletion of amyloid- β^2 peptides from solution by sequestration within fibril-seeded hydrogels. <i>Protein Science</i> , 2018, 27, 1218-1230.	3.1	6
369	The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 2-20.	0.9	77

#	ARTICLE	IF	CITATIONS
370	Toxic HypF-N Oligomers Selectively Bind the Plasma Membrane to Impair Cell Adhesion Capability. <i>Biophysical Journal</i> , 2018, 114, 1357-1367.	0.2	8
371	Microglia-Mediated Synapse Loss in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2018, 38, 2911-2919.	1.7	228
372	An acute functional screen identifies an effective antibody targeting amyloid- β^2 oligomers based on calcium imaging. <i>Scientific Reports</i> , 2018, 8, 4634.	1.6	15
373	Dynamic Nature of presenilin1/ β^3 -Secretase: Implication for Alzheimer's Disease Pathogenesis. <i>Molecular Neurobiology</i> , 2018, 55, 2275-2284.	1.9	24
374	Inhibition of Poly(ADP-ribose) Polymerase-1 Enhances Gene Expression of Selected Sirtuins and APP Cleaving Enzymes in Amyloid Beta Cytotoxicity. <i>Molecular Neurobiology</i> , 2018, 55, 4612-4623.	1.9	27
375	The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases. <i>Neurobiology of Disease</i> , 2018, 109, 178-190.	2.1	62
376	Patrones de retenci3n de 11 C-PIB en la sustancia blanca y en la sustancia gris cerebral de pacientes con hidrocefalia a presi3n normal idiop3tica. Un an3lisis visual. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 87-93.	0.0	1
377	Amyloid and membrane complexity: The toxic interplay revealed by AFM. <i>Seminars in Cell and Developmental Biology</i> , 2018, 73, 82-94.	2.3	34
378	Rational design of a sense and treat system to target amyloid aggregates related to Alzheimer's disease. <i>Nano Research</i> , 2018, 11, 1987-1997.	5.8	21
379	Seed-induced A β^2 deposition is modulated by microglia under environmental enrichment in a mouse model of Alzheimer's disease. <i>EMBO Journal</i> , 2018, 37, 167-182.	3.5	87
380	Amyloid β^2 oligomers (A β^2 Os) in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 177-191.	1.4	114
381	Q&A: Array tomography. <i>BMC Biology</i> , 2018, 16, 98.	1.7	55
382	Deficient Wnt Signaling and Synaptic Vulnerability in Alzheimer's Disease: Emerging Roles for the LRP6 Receptor. <i>Frontiers in Synaptic Neuroscience</i> , 2018, 10, 38.	1.3	30
383	In vivo coupling of tau pathology and cortical thinning in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 678-687.	1.2	24
384	The Role of Glial Cells and Synapse Loss in Mouse Models of Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 473.	1.8	24
385	Synaptosomes. <i>Neuromethods</i> , 2018, , .	0.2	3
386	Light at the End of the Amyloid Tunnel. <i>Biochemistry</i> , 2018, 57, 5921-5922.	1.2	12
387	Shear-Induced Amyloid Formation in the Brain: IV. Effects on Synapses Surrounding Senile Plaque and in Plaque-Free Regions. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 57-73.	1.2	4

#	ARTICLE	IF	CITATIONS
388	High affinity interactions and signal transduction between A β oligomers and TREM2. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	86
389	Inflammasome signalling in brain function and neurodegenerative disease. <i>Nature Reviews Neuroscience</i> , 2018, 19, 610-621.	4.9	514
390	Dihydrochalcone molecules destabilize Alzheimer's amyloid- β protofibrils through binding to the protofibril cavity. <i>Physical Chemistry Chemical Physics</i> , 2018, 20, 17208-17217.	1.3	32
391	Higher Blood Vitamin C Levels are Associated with Reduction of Apolipoprotein E E4-related Risks of Cognitive Decline in Women: The Nakajima Study. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1289-1297.	1.2	15
392	Improved synaptic and cognitive function in aged 3 \times Tg-AD mice with reduced amyloid- β after immunotherapy with a novel recombinant 6A β 15-TF chimeric vaccine. <i>Clinical Immunology</i> , 2018, 193, 12-23.	1.4	4
393	Tailoring Hydrophobic Interactions between Probes and Amyloid- β Peptides for Fluorescent Monitoring of Amyloid- β Aggregation. <i>ACS Omega</i> , 2018, 3, 5141-5154.	1.6	7
394	Translational opportunities for amyloid-targeting fluorophores. <i>Chemical Communications</i> , 2018, 54, 9107-9118.	2.2	27
395	Adenosine Receptors in Alzheimer's Disease. , 2018, , 259-280.		5
396	Nanosopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal Cells. <i>ChemBioChem</i> , 2018, 19, 2033-2038.	1.3	52
397	Efficient clearance of A β protofibrils in A β PP-transgenic mice treated with a brain-penetrating bifunctional antibody. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 49.	3.0	49
398	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. <i>Frontiers in Neuroscience</i> , 2018, 12, 37.	1.4	132
399	Chronic ghrelin administration restores hippocampal long-term potentiation and ameliorates memory impairment in rat model of Alzheimer's disease. <i>Hippocampus</i> , 2018, 28, 724-734.	0.9	44
400	Stabilization and Characterization of Cytotoxic A β ₄₀ Oligomers Isolated from an Aggregation Reaction in the Presence of Zinc Ions. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2959-2971.	1.7	42
401	Chinese Herbal Medicine Xueshuantong Enhances Cerebral Blood Flow and Improves Neural Functions in Alzheimer's Disease Mice. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1089-1107.	1.2	20
402	What Happens with the Circuit in Alzheimer's Disease in Mice and Humans?. <i>Annual Review of Neuroscience</i> , 2018, 41, 277-297.	5.0	154
403	Soluble amyloid-beta buffering by plaques in Alzheimer disease dementia versus high-pathology controls. <i>PLoS ONE</i> , 2018, 13, e0200251.	1.1	9
404	Aptamers Selected for Recognizing Amyloid β -Protein: A Case for Cautious Optimism. <i>International Journal of Molecular Sciences</i> , 2018, 19, 668.	1.8	14
405	Cellular Receptors of Amyloid β Oligomers (A β O _s) in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1884.	1.8	66

#	ARTICLE	IF	CITATIONS
406	Postsynaptic Proteome of Non-Demented Individuals with Alzheimer's Disease Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 659-682.	1.2	31
407	Importance of GPCR-Mediated Microglial Activation in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 258.	1.8	31
408	Antibody-Based In Vivo PET Imaging Detects Amyloid- β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1885-1891.	2.8	32
409	The Amyloid- β Oligomer Hypothesis: Beginning of the Third Decade. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S567-S610.	1.2	572
410	Methods for array tomography with correlative light and electron microscopy. <i>Medical Molecular Morphology</i> , 2019, 52, 8-14.	0.4	6
411	PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. <i>Neuroscience Letters</i> , 2019, 691, 44-50.	1.0	85
412	New role of P2X7 receptor in an Alzheimer's disease mouse model. <i>Molecular Psychiatry</i> , 2019, 24, 108-125.	4.1	118
413	MGCD0103, a selective histone deacetylase inhibitor, ameliorates oligomeric A β -induced anxiety and cognitive deficits in a mouse model. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 175-186.	1.9	15
414	A vicious cycle of amyloid-dependent neuronal hyperactivation. <i>Science</i> , 2019, 365, 559-565.	6.0	407
415	Early network dysfunction in Alzheimer's disease. <i>Science</i> , 2019, 365, 540-541.	6.0	68
416	Targeting the Synapse in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 735.	1.4	163
417	Rosa canina L. methanolic extract prevents heat stress-induced memory dysfunction in rats. <i>Experimental Physiology</i> , 2019, 104, 1544-1554.	0.9	20
418	The molecular lifecycle of amyloid - Mechanism of assembly, mesoscopic organisation, polymorphism, suprastructures, and biological consequences. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2019, 1867, 140257.	1.1	35
419	Emerging links between cell competition and Alzheimer's disease. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	12
420	Imbalance in the response of pre- and post-synaptic components to amyloidopathy. <i>Scientific Reports</i> , 2019, 9, 14837.	1.6	15
421	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 597-609.	1.8	44
422	Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1910-1923.	1.2	61
423	Hexahydropyrrolo[2,3- <i>b</i>]indole Compounds as Potential Therapeutics for Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4250-4263.	1.7	9

#	ARTICLE	IF	CITATIONS
424	Inflammatory mechanisms in neurodegeneration. <i>Journal of Neurochemistry</i> , 2019, 149, 562-581.	2.1	85
425	Reduced presynaptic vesicle stores mediate cellular and network plasticity defects in an early-stage mouse model of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2019, 14, 7.	4.4	52
426	New insights into the role of microRNAs and long noncoding RNAs in most common neurodegenerative diseases. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 8908-8918.	1.2	33
427	New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease. <i>Neuropharmacology</i> , 2019, 155, 131-141.	2.0	67
428	Hippocampal stem cells promotes synaptic resistance to the dysfunctional impact of amyloid beta oligomers via secreted exosomes. <i>Molecular Neurodegeneration</i> , 2019, 14, 25.	4.4	38
429	Clusterin accumulates in synapses in Alzheimer's disease and is increased in apolipoprotein E4 carriers. <i>Brain Communications</i> , 2019, 1, fcz003.	1.5	42
430	Transfer of the Experimental Autoimmune Glaucoma Model from Rats to Mice—New Options to Study Glaucoma Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2563.	1.8	17
431	CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice. <i>Neurotherapeutics</i> , 2019, 16, 710-724.	2.1	60
432	The Toxicity of Misfolded Protein Oligomers Is Independent of Their Secondary Structure. <i>ACS Chemical Biology</i> , 2019, 14, 1593-1600.	1.6	34
433	Blood amyloid- β oligomerization associated with neurodegeneration of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 40.	3.0	38
434	Label-free distribution of anti-amyloid β AIP in <i>Drosophila melanogaster</i> : prevention of $A\beta$ induced toxicity without side effects in transgenic flies. <i>Journal of Neurochemistry</i> , 2019, 150, 74-87.	2.1	7
435	X-ray Absorption Spectroscopy Investigations of Copper(II) Coordination in the Human Amyloid β Peptide. <i>Inorganic Chemistry</i> , 2019, 58, 6294-6311.	1.9	30
436	A Unifying Hypothesis for Alzheimer's Disease: From Plaques to Neurodegeneration. <i>Trends in Neurosciences</i> , 2019, 42, 310-322.	4.2	99
437	Ultrastructural evidence of microglial heterogeneity in Alzheimer's disease amyloid pathology. <i>Journal of Neuroinflammation</i> , 2019, 16, 87.	3.1	73
438	Effect of <i>Alpinia oxyphylla</i> — <i>Schisandra chinensis</i> herb pair on inflammation and apoptosis in Alzheimer's disease mice model. <i>Journal of Ethnopharmacology</i> , 2019, 237, 28-38.	2.0	29
439	Nanoscale structure of amyloid- β plaques in Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 5181.	1.6	52
440	Amyloid β oligomers suppress excitatory transmitter release via presynaptic depletion of phosphatidylinositol-4,5-bisphosphate. <i>Nature Communications</i> , 2019, 10, 1193.	5.8	92
441	Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity. <i>International Journal of Molecular Sciences</i> , 2019, 20, 901.	1.8	81

#	ARTICLE	IF	CITATIONS
442	The Amazon rain forest plant <i>Uncaria tomentosa</i> (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. <i>Scientific Reports</i> , 2019, 9, 561.	1.6	42
443	Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 63.	1.8	99
444	Glial Control of Synapse Number in Healthy and Diseased Brain. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 42.	1.8	67
445	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. <i>Laboratory Investigation</i> , 2019, 99, 958-970.	1.7	82
446	Alzheimer's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 231-255.	1.0	415
447	Pathological mitochondria in neurons and perivascular astrocytic endfeet of idiopathic normal pressure hydrocephalus patients. <i>Fluids and Barriers of the CNS</i> , 2019, 16, 39.	2.4	26
448	Puerariae Radix Prevents Anxiety and Cognitive Deficits in Mice Under Oligomeric A β -Induced Stress. <i>The American Journal of Chinese Medicine</i> , 2019, 47, 1459-1481.	1.5	17
449	Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer's Disease. <i>Cell Reports</i> , 2019, 29, 3592-3604.e5.	2.9	123
450	Synapsin 1 promotes A β generation via BACE1 modulation. <i>PLoS ONE</i> , 2019, 14, e0226368.	1.1	10
451	Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric A β . <i>Alzheimer's Research and Therapy</i> , 2019, 11, 97.	3.0	22
452	Involvement of calpain in the neuropathogenesis of Alzheimer's disease. <i>Medicinal Research Reviews</i> , 2019, 39, 608-630.	5.0	70
453	Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 429-440.	0.4	69
454	Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 303-313.	1.9	40
455	Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies. , 2019, 195, 186-198.		141
456	The Anti-amyloid Compound DO1 Decreases Plaque Pathology and Neuroinflammation-Related Expression Changes in 5xFAD Transgenic Mice. <i>Cell Chemical Biology</i> , 2019, 26, 109-120.e7.	2.5	8
457	The amyloid precursor protein (APP) processing as a biological link between Alzheimer's disease and cancer. <i>Ageing Research Reviews</i> , 2019, 49, 83-91.	5.0	49
458	A β oligomers trigger and accelerate A β seeding. <i>Brain Pathology</i> , 2020, 30, 36-45.	2.1	62
459	Intraventricular murine A β infusion elicits hippocampal inflammation and disrupts the consolidation, but not retrieval, of conditioned fear in C57BL/6J mice. <i>Behavioural Brain Research</i> , 2020, 378, 112303.	1.2	3

#	ARTICLE	IF	CITATIONS
460	ATR-IR and EPR spectroscopy for detecting the alterations in cortical synaptosomes induced by aluminium stress. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2020, 228, 117535.	2.0	8
461	Prolonged isolation stress accelerates the onset of Alzheimer's disease-related pathology in 5xFAD mice despite running wheels and environmental enrichment. <i>Behavioural Brain Research</i> , 2020, 379, 112366.	1.2	22
462	A KLVFFAE-Derived Peptide Probe for Detection of Alpha-Synuclein Fibrils. <i>Applied Biochemistry and Biotechnology</i> , 2020, 190, 1411-1424.	1.4	3
463	Systematic Quantification of Synapses in Primary Neuronal Culture. <i>IScience</i> , 2020, 23, 101542.	1.9	22
464	The Dual Role of Glutamatergic Neurotransmission in Alzheimer's Disease: From Pathophysiology to Pharmacotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7452.	1.8	63
465	Parallels between retinal and brain pathology and response to immunotherapy in old, late-stage Alzheimer's disease mouse models. <i>Aging Cell</i> , 2020, 19, e13246.	3.0	32
466	Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease. <i>Cell</i> , 2020, 182, 976-991.e19.	13.5	491
467	Caspase Activation and Caspase-Mediated Cleavage of APP Is Associated with Amyloid β -Protein-Induced Synapse Loss in Alzheimer's Disease. <i>Cell Reports</i> , 2020, 31, 107839.	2.9	45
468	Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 967-979.	1.2	36
469	Anti- $A\beta$ antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology. <i>Acta Neuropathologica Communications</i> , 2020, 8, 198.	2.4	7
470	MERCs. The Novel Assistant to Neurotransmission?. <i>Frontiers in Neuroscience</i> , 2020, 14, 589319.	1.4	12
471	Multiscale causal networks identify VGF as a key regulator of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 3942.	5.8	94
472	The physiological roles of tau and $A\beta$: implications for Alzheimer's disease pathology and therapeutics. <i>Acta Neuropathologica</i> , 2020, 140, 417-447.	3.9	221
473	Pharmacological intervention to restore connectivity deficits of neuronal networks derived from ASD patient iPSC with a TSC2 mutation. <i>Molecular Autism</i> , 2020, 11, 80.	2.6	25
474	Axonal Degeneration in AD: The Contribution of $A\beta$ and Tau. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 581767.	1.7	28
475	Hippocampal alterations in glutamatergic signaling during amyloid progression in $A\beta$ PP/PS1 mice. <i>Scientific Reports</i> , 2020, 10, 14503.	1.6	23
476	Mechanisms of Pathogenic Tau and $A\beta$ Protein Spreading in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 265.	1.7	78
477	Synaptic Loss in Alzheimer's Disease: Mechanistic Insights Provided by Two-Photon in vivo Imaging of Transgenic Mouse Models. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 592607.	1.8	47

#	ARTICLE	IF	CITATIONS
478	Vaccination against β -Amyloid as a Strategy for the Prevention of Alzheimer's Disease. <i>Biology</i> , 2020, 9, 425.	1.3	26
479	Ca ²⁺ Dyshomeostasis Disrupts Neuronal and Synaptic Function in Alzheimer's Disease. <i>Cells</i> , 2020, 9, 2655.	1.8	33
480	Space-Dependent Glia-Neuron Interplay in the Hippocampus of Transgenic Models of β -Amyloid Deposition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9441.	1.8	9
481	Telescoping the Synthesis of the [¹⁸ F]CABS13 Alzheimer's Disease Radiopharmaceutical via Flow Microfluidic Rhenium(I) Complexations. <i>European Journal of Inorganic Chemistry</i> , 2020, 2020, 3554-3564.	1.0	2
482	Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9318.	1.8	54
483	Synapse and Receptor Alterations in Two Different S100B-Induced Glaucoma-Like Models. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6998.	1.8	3
484	The Role of Synaptic Dysfunction in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 49-62.	1.2	13
485	Molecular, Structural, Functional, and Pharmacological Sites for Vesicular Glutamate Transporter Regulation. <i>Molecular Neurobiology</i> , 2020, 57, 3118-3142.	1.9	31
486	The Role of P2X7 Receptor in Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 94.	1.4	44
487	Allosteric modulation of AMPA receptors counteracts Tau-related excitotoxic synaptic signaling and memory deficits in stress- and $A\beta$ -evoked hippocampal pathology. <i>Molecular Psychiatry</i> , 2021, 26, 5899-5911.	4.1	12
488	A single-synapse resolution survey of PSD95-positive synapses in twenty human brain regions. <i>European Journal of Neuroscience</i> , 2021, 54, 6864-6881.	1.2	21
489	Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 3258-3272.	1.9	33
490	Astrocyte Senescence and Alzheimer's Disease: A Review. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 148.	1.7	81
491	A mechanistic hypothesis for the impairment of synaptic plasticity by soluble $A\beta$ oligomers from Alzheimer's brain. <i>Journal of Neurochemistry</i> , 2020, 154, 583-597.	2.1	158
492	An RNA aptamer with potent affinity for a toxic dimer of amyloid $A\beta$ has potential utility for histochemical studies of Alzheimer's disease. <i>Journal of Biological Chemistry</i> , 2020, 295, 4870-4880.	1.6	18
493	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 21.	3.0	183
494	Complexity in Lipid Membrane Composition Induces Resilience to $A\beta$ Aggregation. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1347-1352.	1.7	22
495	Chronic oral administration of adipoRon reverses cognitive impairments and ameliorates neuropathology in an Alzheimer's disease mouse model. <i>Molecular Psychiatry</i> , 2021, 26, 5669-5689.	4.1	47

#	ARTICLE	IF	CITATIONS
496	Half a century of amyloids: past, present and future. <i>Chemical Society Reviews</i> , 2020, 49, 5473-5509.	18.7	345
497	Polarity-activated super-resolution imaging probe for the formation and morphology of amyloid fibrils. <i>Nano Research</i> , 2020, 13, 2556-2563.	5.8	12
498	Bloodâ€“brain barrier damage and dysfunction by chemical toxicity. , 2020, , 811-827.		0
499	ATR-IR and EPR spectroscopy for following the membrane restoration of isolated cortical synaptosomes in aluminium-induced Alzheimerâ€™s disease â€“ Like rat model. <i>Chemistry and Physics of Lipids</i> , 2020, 231, 104931.	1.5	4
500	Synaptic mitochondrial dysfunction and septin accumulation are linked to complement-mediated synapse loss in an Alzheimerâ€™s disease animal model. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 5243-5258.	2.4	39
501	Amyloid β -protein and beyond: the path forward in Alzheimerâ€™s disease. <i>Current Opinion in Neurobiology</i> , 2020, 61, 116-124.	2.0	87
502	Chronic Presence of Oligomeric $A\beta$ Differentially Modulates Spine Parameters in the Hippocampus and Cortex of Mice With Low APP Transgene Expression. <i>Frontiers in Synaptic Neuroscience</i> , 2020, 12, 16.	1.3	7
503	Dynamics of oligomer populations formed during the aggregation of Alzheimerâ€™s $A\beta_{42}$ peptide. <i>Nature Chemistry</i> , 2020, 12, 445-451.	6.6	223
504	Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimerâ€™s Disease in Health Screening Population. <i>Diagnostics</i> , 2020, 10, 237.	1.3	9
505	Oligomeric amyloid- β induces early and widespread changes to the proteome in human iPSC-derived neurons. <i>Scientific Reports</i> , 2020, 10, 6538.	1.6	18
506	Maintained memory and longâ€“term potentiation in a mouse model of Alzheimer's disease with both amyloid pathology and human tau. <i>European Journal of Neuroscience</i> , 2021, 53, 637-648.	1.2	4
507	β -amyloid pathology is not associated with depression in a large community sample autopsy study. <i>Journal of Affective Disorders</i> , 2021, 278, 372-381.	2.0	12
508	Protofibrilâ€“Fibril Interactions Inhibit Amyloid Fibril Assembly by Obstructing Secondary Nucleation. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 3016-3021.	7.2	21
509	Sigma ligands as potent inhibitors of $A\beta$ and $A\beta$ O _s in neurons and promising therapeutic agents of Alzheimer's disease. <i>Neuropharmacology</i> , 2021, 190, 108342.	2.0	8
510	Untangling the association of amyloid- β and tau with synaptic and axonal loss in Alzheimerâ€™s disease. <i>Brain</i> , 2021, 144, 310-324.	3.7	123
511	Recognition and Removal of Amyloidâ€“ β by a Heteromultivalent Macrocyclic Coassembly: A Potential Strategy for the Treatment of Alzheimer's Disease. <i>Advanced Materials</i> , 2021, 33, e2006483.	11.1	39
512	The interaction of insoluble Amyloidâ€“ β with soluble Amyloidâ€“ β dimers decreases Amyloidâ€“ β plaque numbers. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 603-610.	1.8	3
513	Identification of intraneuronal amyloid beta oligomers in locus coeruleus neurons of Alzheimerâ€™s patients and their potential impact on inhibitory neurotransmitter receptors and neuronal excitability. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 488-505.	1.8	25

#	ARTICLE	IF	CITATIONS
514	Protofibrilâ€Fibril Interactions Inhibit Amyloid Fibril Assembly by Obstructing Secondary Nucleation. <i>Angewandte Chemie</i> , 2021, 133, 3053-3058.	1.6	2
515	Modified Glutamatergic Postsynapse in Neurodegenerative Disorders. <i>Neuroscience</i> , 2021, 454, 116-139.	1.1	14
516	Proteins and Disease The Chemistry of Alzheimer Disease â€ Molecular, Genetic and Physiologic Perspectives. , 2021, , 77-85.		0
517	Preface to the Book Series. , 2021, , xv-xvii.		0
518	The Pathogenesis Mechanism, Structure Properties, Potential Drugs and Therapeutic Nanoparticles against the Small Oligomers of Amyloid-Î². <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 151-167.	1.0	5
519	Origin, toxicity and characteristics of two amyloid oligomer polymorphs. <i>RSC Chemical Biology</i> , 2021, 2, 1631-1642.	2.0	5
520	<i>In vitro</i> and <i>in vivo</i> models for anti-amyloidosis nanomedicines. <i>Nanoscale Horizons</i> , 2021, 6, 95-119.	4.1	13
521	Microvascular Alterations in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 618986.	1.8	41
522	Reverse engineering Lewy bodies: how far have we come and how far can we go?. <i>Nature Reviews Neuroscience</i> , 2021, 22, 111-131.	4.9	104
523	Micro-Raman spectroscopy of lipid halo and dense-core amyloid plaques: aging process characterization in the Alzheimer's disease APP ^{swe} PS1 ^{E9} mouse model. <i>Analyst</i> , The, 2021, 146, 6014-6025.	1.7	4
524	Association of AÎ² deposition and regional synaptic density in early Alzheimerâ€™s disease: a PET imaging study with [11C]UCBJ. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 11.	3.0	53
525	Development of molecular tools for diagnosis of Alzheimerâ€™s disease that are based on detection of amyloidogenic proteins. <i>Prion</i> , 2021, 15, 56-69.	0.9	12
526	Flow cytometry method to quantify the formation of beta-amyloid membrane ion channels.. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2021, 1863, 183506.	1.4	12
527	Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. <i>Nature Reviews Chemistry</i> , 2021, 5, 277-294.	13.8	56
528	Insight into the role of phosphatidylserine in complement-mediated synapse loss in Alzheimerâ€™s disease. <i>Faculty Reviews</i> , 2021, 10, 19.	1.7	17
529	The release of toxic oligomers from Î±-synuclein fibrils induces dysfunction in neuronal cells. <i>Nature Communications</i> , 2021, 12, 1814.	5.8	123
530	The Diagnostic Potential of Amyloidogenic Proteins. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4128.	1.8	7
531	Transcriptional signature in microglia associated with AÎ² plaque phagocytosis. <i>Nature Communications</i> , 2021, 12, 3015.	5.8	142

#	ARTICLE	IF	CITATIONS
532	Exploring the Release of Toxic Oligomers from β -Synuclein Fibrils with Antibodies and STED Microscopy. <i>Life</i> , 2021, 11, 431.	1.1	17
533	Tripartite Relationship Among Synaptic, Amyloid, and Tau Proteins: An In Vivo and Postmortem Study. <i>Neurology</i> , 2021, , 10.1212/WNL.0000000000012145.	1.5	8
534	VEGF counteracts amyloid- β -induced synaptic dysfunction. <i>Cell Reports</i> , 2021, 35, 109121.	2.9	19
535	Atrophy of lacunosum moleculare layer is important for learning and memory in APP/PS1 transgenic mice. <i>NeuroReport</i> , 2021, 32, 596-602.	0.6	3
536	The role of amyloid oligomers in neurodegenerative pathologies. <i>International Journal of Biological Macromolecules</i> , 2021, 181, 582-604.	3.6	38
537	Single molecule imaging of protein aggregation in Dementia: Methods, insights and prospects. <i>Neurobiology of Disease</i> , 2021, 153, 105327.	2.1	2
538	A computational grid-to-place-cell transformation model indicates a synaptic driver of place cell impairment in early-stage Alzheimer's Disease. <i>PLoS Computational Biology</i> , 2021, 17, e1009115.	1.5	4
539	Hippocampal Somatostatin Interneurons, Long-Term Synaptic Plasticity and Memory. <i>Frontiers in Neural Circuits</i> , 2021, 15, 687558.	1.4	32
540	The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer's Disease. <i>Medical Science Monitor</i> , 2021, 27, e933084.	0.5	10
541	An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5991.	1.8	28
543	Alzheimer's Disease, Neural Plasticity, and Functional Recovery. <i>Journal of Alzheimer's Disease</i> , 2021, 82, S37-S50.	1.2	24
544	Exogenous misfolded protein oligomers can cross the intestinal barrier and cause a disease phenotype in <i>C. elegans</i> . <i>Scientific Reports</i> , 2021, 11, 14391.	1.6	6
545	Plexin-A4 mediates amyloid- β -induced tau pathology in Alzheimer's disease animal model. <i>Progress in Neurobiology</i> , 2021, 203, 102075.	2.8	5
546	Reference interval and the role of plasma oligomeric beta amyloid in screening of risk groups for cognitive dysfunction at health checkups. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23933.	0.9	3
547	Identification of ortho catechol-containing isoflavone as a privileged scaffold that directly prevents the aggregation of both amyloid β plaques and tau-mediated neurofibrillary tangles and its in vivo evaluation. <i>Bioorganic Chemistry</i> , 2021, 113, 105022.	2.0	7
548	The impaired unfolded protein α -premelanosome protein and transient receptor potential channels α -autophagy axes in apoptotic melanocytes in vitiligo. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 6-17.	1.5	6
549	The Amyloid- β Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021, 26, 5481-5503.	4.1	478
551	Green Tea Polyphenol Epigallocatechin-Gallate in Amyloid Aggregation and Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , 2021, 15, 718188.	1.4	39

#	ARTICLE	IF	CITATIONS
552	Oligomeric and Fibrillar Species of A β 242 Diversely Affect Human Neural Stem Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9537.	1.8	4
553	Flavanonol Glycosides from the Stems of <i>Myrsine seguinii</i> and Their Neuroprotective Activities. <i>Pharmaceuticals</i> , 2021, 14, 911.	1.7	1
554	Depichering the Effects of Astragaloside IV on AD-Like Phenotypes: A Systematic and Experimental Investigation. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-21.	1.9	14
555	Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. <i>Alzheimer's and Dementia</i> , 2021, 17, 1365-1382.	0.4	43
556	Flow Cytometric Evaluation of Crude Synaptosome Preparation as a Way to Study Synaptic Alteration in Neurodegenerative Diseases. <i>Neuromethods</i> , 2018, 141, 297-310.	0.2	5
557	Protein Aggregation Diseases: Toxicity of Soluble Prefibrillar Aggregates and Their Clinical Significance. <i>Methods in Molecular Biology</i> , 2010, 648, 25-41.	0.4	21
558	Overview of Fibrillar and Oligomeric Assemblies of Amyloidogenic Proteins. , 2012, , 1-36.		3
559	Bacterial Amyloids: Biogenesis and Biomaterials. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1174, 113-159.	0.8	7
560	Protein Microgels from Amyloid Fibril Networks. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1174, 223-263.	0.8	10
561	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 94, 71-80.	1.5	14
562	SEQUIN Multiscale Imaging of Mammalian Central Synapses Reveals Loss of Synaptic Connectivity Resulting from Diffuse Traumatic Brain Injury. <i>Neuron</i> , 2020, 107, 257-273.e5.	3.8	30
563	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. <i>Brain Communications</i> , 2020, 2, fcaa177.	1.5	10
569	Activation of CaMKIV by soluble amyloid- β 2 impeded trafficking of axonal vesicles and impairs activity-dependent synaptogenesis. <i>Science Signaling</i> , 2017, 10, .	1.6	30
570	Misfolded Proteins in Neurodegenerative Dementias: Molecular Mechanisms. <i>Dementia and Neurocognitive Disorders</i> , 2012, 11, 38.	0.4	2
571	Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e89454.	1.1	101
572	Synapse Density and Dendritic Complexity Are Reduced in the Prefrontal Cortex following Seven Days of Forced Abstinence from Cocaine Self-Administration. <i>PLoS ONE</i> , 2014, 9, e102524.	1.1	35
573	Imbalance in Fatty-Acid-Chain Length of Gangliosides Triggers Alzheimer Amyloid Deposition in the Precuneus. <i>PLoS ONE</i> , 2015, 10, e0121356.	1.1	35
574	Large Soluble Oligomers of Amyloid β -Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. <i>Journal of Neuroscience</i> , 2017, 37, 152-163.	1.7	19

#	ARTICLE	IF	CITATIONS
576	A β Plaques. Free Neuropathology, 2020, 1, .	2.4	21
578	Spermidine and spermine delay brain aging by inducing autophagy in SAMP8 mice. Aging, 2020, 12, 6401-6414.	1.4	85
579	Therapeutic Strategies Targeting Amyloid- β in Alzheimer's Disease. Current Alzheimer Research, 2019, 16, 418-452.	0.7	88
580	Amyloid Oligomer Structures and Toxicity. The Open Biology Journal, 2009, 2, 222-227.	0.5	5
581	Opposing Roles of apolipoprotein E in aging and neurodegeneration. Life Science Alliance, 2019, 2, e201900325.	1.3	20
582	The synaptic pathology of cognitive life. Dialogues in Clinical Neuroscience, 2019, 21, 271-279.	1.8	13
583	High-Resolution Ocular Imaging: Combining Advanced Optics and Microtechnology. Ophthalmic Surgery Lasers and Imaging Retina, 2009, 40, 480-488.	0.4	8
584	Challenges in understanding the structure/activity relationship of A β oligomers. AIMS Biophysics, 2019, 6, 1-22.	0.3	3
585	Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies. Indian Journal of Pharmacology, 2016, 48, 629.	0.4	57
586	On the road towards the global analysis of human synapses. Neural Regeneration Research, 2017, 12, 1586.	1.6	6
587	Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. Neural Regeneration Research, 2018, 13, 616.	1.6	106
588	Physiological and pathological effects of amyloid- β species in neural stem cell biology. Neural Regeneration Research, 2019, 14, 2035.	1.6	22
589	Presynaptic APP levels and synaptic homeostasis are regulated by Akt phosphorylation of huntingtin. ELife, 2020, 9, .	2.8	21
590	The Essentials of Biochemistry of the Proteins as Related to Alzheimer's Disease: A Review. International Journal of Biochemistry Research & Review, 0, , 34-49.	0.1	2
591	Amyloid- β -dependent and amyloid- β -independent effects of Tau in individuals without dementia. Annals of Clinical and Translational Neurology, 2021, 8, 2083-2092.	1.7	7
592	Nanomaterials for neurodegenerative diseases: Molecular mechanisms guided design and applications. Nano Research, 2022, 15, 3299-3322.	5.8	7
594	Intraneuronal Amyloid and Cognitive Impairment. , 2016, , 133-137.		0
595	Bio-Targets for Polyionic Glucan Derivatives and Their Nano- Therapeutic Systems. , 2016, , 487-513.		0

#	ARTICLE	IF	CITATIONS
599	The Amyloid Precursor Protein: More than Just Amyloid- Beta. <i>Journal of Neurology and Experimental Neuroscience</i> , 2019, 05, .	0.2	2
600	Memory Dysfunction Correlates with the Dysregulated Dopaminergic System in the Ventral Tegmental Area in Alzheimer's Disease. , 2019, , 85-98.		0
607	Plaque-Associated Oligomeric Amyloid-Beta Drives Early Synaptotoxicity in APP/PS1 Mice Hippocampus: Ultrastructural Pathology Analysis. <i>Frontiers in Neuroscience</i> , 2021, 15, 752594.	1.4	15
610	Explicating anti-amyloidogenic role of curcumin and piperine via amyloid beta ($A\beta$) explicit pathway: recovery and reversal paradigm effects. <i>PeerJ</i> , 2020, 8, e10003.	0.9	2
611	An ultra-sensitive immunoassay detects and quantifies soluble $A\beta$ oligomers in human plasma. <i>Alzheimer's and Dementia</i> , 2022, 18, 1186-1202.	0.4	18
612	Precision Mapping of Amyloid- β Binding Reveals Perisynaptic Localization and Spatially Restricted Plasticity Deficits. <i>ENeuro</i> , 2021, , ENEURO.0416-21.2021.	0.9	2
613	The role of pathological tau in synaptic dysfunction in Alzheimer's diseases. <i>Translational Neurodegeneration</i> , 2021, 10, 45.	3.6	66
614	Presenilin-3-Secretase Activity Is Located in Acidic Compartments of Live Neurons. <i>Journal of Neuroscience</i> , 2022, 42, 145-154.	1.7	19
616	Cerebral dysfunctions caused by sepsis during ageing. <i>Nature Reviews Immunology</i> , 2022, 22, 444-458.	10.6	55
617	Biological and methodological complexities of beta-amyloid peptide: Implications for Alzheimer's disease research. <i>Journal of Neurochemistry</i> , 2022, 160, 434-453.	2.1	12
618	Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and A β pathology. <i>Nature Communications</i> , 2022, 13, 135.	5.8	97
619	Optogenetic stimulation of CA3 pyramidal neurons restores synaptic deficits to improve spatial short-term memory in APP/PS1 mice. <i>Progress in Neurobiology</i> , 2022, 209, 102209.	2.8	9
620	Synaptic dysfunction in early phases of Alzheimer's Disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2022, 184, 417-438.	1.0	27
621	Amyloid- β oligomers in the nucleus accumbens decrease motivation via insertion of calcium-permeable AMPA receptors. <i>Molecular Psychiatry</i> , 2022, 27, 2146-2157.	4.1	5
622	Site-Directed Chemical Modification of Amyloid by Polyoxometalates for Inhibition of Protein Misfolding and Aggregation. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	26
623	Site-Directed Chemical Modification of Amyloid by Polyoxometalates for Inhibition of Protein Misfolding and Aggregation. <i>Angewandte Chemie</i> , 2022, 134, .	1.6	4
624	Reducing voltage-dependent potassium channel Kv3.4 levels ameliorates synapse loss in a mouse model of Alzheimer's disease. <i>Brain and Neuroscience Advances</i> , 2022, 6, 239821282210864.	1.8	6
625	Optical tissue clearing associated with 3D imaging: application in preclinical and clinical studies. <i>Histochemistry and Cell Biology</i> , 2022, 157, 497-511.	0.8	10

#	ARTICLE	IF	CITATIONS
626	Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review. <i>European Journal of Neuroscience</i> , 2022, 56, 5650-5713.	1.2	4
627	A β^2 oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2022, 10, 31.	2.4	28
628	Synaptic degeneration in the prefrontal cortex of a rat AD model revealed by volume electron microscopy. <i>Journal of Molecular Cell Biology</i> , 2022, 14, .	1.5	2
629	Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 174.	2.4	45
630	Impairments of glutamatergic synaptic transmission in Alzheimer's disease. <i>Seminars in Cell and Developmental Biology</i> , 2023, 139, 24-34.	2.3	15
631	Emerging insights into synapse dysregulation in Alzheimer's disease. <i>Brain Communications</i> , 2022, 4, .	1.5	16
634	Elevated amyloid beta disrupts the nanoscale organization and function of synaptic vesicle pools in hippocampal neurons. <i>Cerebral Cortex</i> , 2023, 33, 1263-1276.	1.6	5
635	Long-term dynamics of aberrant neuronal activity in awake Alzheimer's disease transgenic mice. <i>Communications Biology</i> , 2021, 4, 1368.	2.0	14
636	The synapse as a treatment avenue for Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2022, 27, 2940-2949.	4.1	48
646	Alzheimer's Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint. <i>Frontiers in Neuroscience</i> , 2022, 16, 837390.	1.4	12
647	ACU193: An Immunotherapeutic Poised to Test the Amyloid β^2 Oligomer Hypothesis of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, 848215.	1.4	17
648	Bioactive human Alzheimer brain soluble A β^2 : pathophysiology and therapeutic opportunities. <i>Molecular Psychiatry</i> , 2022, 27, 3182-3191.	4.1	14
649	PET Imaging in Preclinical Anti-A β^2 Drug Development. <i>Pharmaceutical Research</i> , 2022, 39, 1481-1496.	1.7	7
651	Do Sleep Disturbances have a Dual Effect on Alzheimer's Disease?. <i>Cellular and Molecular Neurobiology</i> , 2023, 43, 711-727.	1.7	1
652	Amyloid β^2 Dodecamer Disrupts the Neuronal Membrane More Strongly than the Mature Fibril: Understanding the Role of Oligomers in Neurotoxicity. <i>Journal of Physical Chemistry B</i> , 2022, 126, 3659-3672.	1.2	9
654	Synapse pathology in Alzheimer's disease. <i>Seminars in Cell and Developmental Biology</i> , 2023, 139, 13-23.	2.3	30
655	Analyzing of Alzheimer's Disease Based on Biomedical and Socio-Economic Approach Using Molecular Communication, Artificial Neural Network, and Random Forest Models. <i>Sustainability</i> , 2022, 14, 7901.	1.6	10
656	Near-Infrared Fluorescent Probes as Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8550-8595.	2.9	29

#	ARTICLE	IF	CITATIONS
657	Cysteine string protein-alpha accumulates with early pre-synaptic dysfunction in Alzheimer's disease. Brain Communications, 0, , .	1.5	3
658	Î²-secretase inhibition prevents structural spine plasticity deficits in AppNL-G-F mice. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
659	Nanomedicines targeting the inflammasome as a promising therapeutic approach for cell senescence. Seminars in Cancer Biology, 2022, 86, 46-53.	4.3	2
660	Modeling the early stages of Alzheimer's disease by administering intracerebroventricular injections of human native AÎ² oligomers to rats. Acta Neuropathologica Communications, 2022, 10, .	2.4	11
661	FSTL1-knockdown improves neural oscillation via decreasing neuronal-inflammation regulating apoptosis in AÎ²1â€“42 induced AD model mice. Experimental Neurology, 2023, 359, 114231.	2.0	2
662	Cellular changes at the glia-neuro-vascular interface in definite idiopathic normal pressure hydrocephalus. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	2
664	Alzheimer's disease: Pathophysiology and dental pulp stem cells therapeutic prospects. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	1
666	Examination of Longitudinal Alterations in Alzheimer's Disease-Related Neurogenesis in an APP/PS1 Transgenic Mouse Model, and the Effects of P33, a Putative Neuroprotective Agent Thereon. International Journal of Molecular Sciences, 2022, 23, 10364.	1.8	3
667	Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases. BioEssays, 2022, 44, .	1.2	14
668	APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases. Molecular Neurodegeneration, 2022, 17, .	4.4	62
669	Inflamasi dalam Patologi Penyakit Alzheimer. , 2020, 33, 65-71.		0
670	Moringa Oleifera Alleviates AÎ² Burden and Improves Synaptic Plasticity and Cognitive Impairments in APP/PS1 Mice. Nutrients, 2022, 14, 4284.	1.7	7
671	Synaptogenic effect of <i>APP</i> -Swedish mutation in familial Alzheimer's disease. Science Translational Medicine, 2022, 14, .	5.8	29
673	Whole-brain mapping of metabolic alterations in a mouse model of Alzheimer's disease by desorption electrospray ionization mass spectrometry imaging. Talanta, 2023, 253, 124046.	2.9	3
674	Amyloid Beta in Aging and Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 12924.	1.8	50
675	Manipulation of the diet's "microbiota" brain axis in Alzheimer's disease. Frontiers in Neuroscience, 0, 16, .	1.4	5
676	Necroptosis and Alzheimer's Disease: Pathogenic Mechanisms and Therapeutic Opportunities. Journal of Alzheimer's Disease, 2023, 94, S367-S386.	1.2	7
677	Physiological Roles of Î²-amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology. Neuroscience Bulletin, 2023, 39, 1289-1308.	1.5	13

#	ARTICLE	IF	CITATIONS
678	Early diagnosis and treatment of Alzheimer's disease by targeting toxic soluble A β oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	18
679	Synaptic degeneration in Alzheimer disease. Nature Reviews Neurology, 2023, 19, 19-38.	4.9	84
680	Zebrafish: A Model Deciphering the Impact of Flavonoids on Neurodegenerative Disorders. Cells, 2023, 12, 252.	1.8	6
681	Microglial Expression of the Wnt Signaling Modulator <i>DKK2</i> Differs between Human Alzheimer's Disease Brains and Mouse Neurodegeneration Models. ENeuro, 2023, 10, ENEURO.0306-22.2022.	0.9	6
682	A genetic variant of the Wnt receptor LRP6 accelerates synapse degeneration during aging and in Alzheimer's disease. Science Advances, 2023, 9, .	4.7	8
683	Self-Assembly of Amyloid Fibrils into 3D Gel Clusters versus 2D Sheets. Biomolecules, 2023, 13, 230.	1.8	1
684	Bringing synapses into focus: Recent advances in synaptic imaging and mass-spectrometry for studying synaptopathy. Frontiers in Synaptic Neuroscience, 0, 15, .	1.3	2
685	Brain region-specific myelinogenesis is not directly linked to amyloid- β in APP/PS1 transgenic mice. Experimental Neurology, 2023, 362, 114344.	2.0	3
686	Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease. Nature Neuroscience, 2023, 26, 406-415.	7.1	41
687	Phospholipase D1 Attenuation Therapeutics Promotes Resilience against Synaptotoxicity in 12-Month-Old 3xTg-AD Mouse Model of Progressive Neurodegeneration. International Journal of Molecular Sciences, 2023, 24, 3372.	1.8	1
688	Amyloid oligomers as on-pathway precursors or off-pathway competitors of fibrils. Frontiers in Molecular Biosciences, 0, 10, .	1.6	6
689	Aza-Residue Modulation of Cyclic <i>d</i> , <i>l</i> -Peptide Nanotube Assembly with Enhanced Anti-Amyloidogenic Activity. Journal of Medicinal Chemistry, 2023, 66, 3058-3072.	2.9	3
690	Insulin-like growth factor-2 is a promising candidate for the treatment and prevention of Alzheimer's disease. CNS Neuroscience and Therapeutics, 2023, 29, 1449-1469.	1.9	2
691	A new class of monoclonal A β antibodies selectively targets and triggers deposition of A β protofibrils. Journal of Neurochemistry, 2023, 165, 860-873.	2.1	2
692	Microglia actively remove <i>NR1</i> autoantibody-bound <i>NMDA</i> receptors and associated postsynaptic proteins in neuron microglia co-cultures. Glia, 2023, 71, 1804-1829.	2.5	0
693	Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 7258.	1.8	7
694	Potential Implication of Treatments for Alzheimer's Disease: Current and Future. , 2023, 36, 3-10.		0
695	Deciphering the multifunctional role of dual leucine zipper kinase (DLK) and its therapeutic potential in disease. European Journal of Medicinal Chemistry, 2023, 255, 115404.	2.6	0

#	ARTICLE	IF	CITATIONS
700	Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. Nature Reviews Neurology, 2023, 19, 395-409.	4.9	54